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ABSTRACT 
 
Cancer-based immunotherapy has led the evolution of biologics that can stimulate immune 
responses towards tumor eradication. For example, the monoclonal antibodies (mAb) and their 
related analogs have shown promise in the clinic for the treatment of a wide range of cancer types. 
In spite of their utility, novel therapeutics that may overcome their production, administration, and 
pharmacological limitations are still in widespread demand. Therefore, the synthesis of small to 
intermediate size molecules with the targeting and effector functions of mAb may represent a novel 
class of immunotherapeutics that may overcome the limitations of their biological counterparts.  
Towards this research objective, B7H6 has been identified as a protein ligand localized on 
the cell surface of transformed tumor cells. It functions as a tumor associated antigen (TAA) which 
binds specifically to the activating receptor NKp30, constitutively expressed on all resting and 
active NK cells. Upon ligand:receptor binding, B7H6 triggers NK cell activation and release of 
chemokines and pro-inflammatory cytokines such as TNF- and IFN-, leading to tumor cell lysis 
and death. Interestingly, B7H6 was found to be expressed on the surface of tumors but not on 
healthy cells making it an interesting bio-marker for NK cell mediated cytotoxicity. Moreover, it 
was recently discovered that tumor cells escape immunosurveillance by the downregulation or 
shedding of B7H6. In an effort to overcome this resistance mechanism, the development of new 
B7H6 derived ligands that may effectively target NKp30 and activate NK cells towards B7H6 
deficient tumors may result in a more effective NK-cell-based cancer therapy approach.  
In this thesis, the rational design of a novel class of immunostimulatory peptides (IPs) 
derived from the binding interface of B7H6:NKp30 was developed. The IPs were composed of the 
B7H6 active site sequence for NKp30 binding and immunostimulatory activity. The addition of 
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an aminohexanoic acid linker was used for FITC-labeling by Fmoc-solid phase peptide synthesis. 
The secondary structures of the peptides were evaluated by CD spectroscopy in H2O, PBS and a 
H2O:TFE mixture which demonstrated flexible peptide structures which adapted to the solvent 
conditions and were found to transition from random coil (H2O) to -helical (PBS) and turn-type 
(H2O:TFE) conformations. The evaluation of their biological properties showed an occupancy of 
the synthetic peptides to a human NK cell line comparable to the natural NKp30 ligand, B7H6, 
and the human anti-NKp30 monoclonal antibody (mAb), in a concentration dependent manner. A 
competitive binding assay in between the human anti-NKp30 mAb or B7H6, and the synthetic 
peptides, demonstrated partial displacement of the ligands upon anti-NKp30 mAb treatment, 
suggesting specific NKp30 receptor binding by the synthetic peptides. Moreover, the 
immunostimulatory activity of B7H6 was demonstrated by the secretion of the pro-inflammatory 
cytokines, tumor necrosis factor-alfa (TNF- and interferon gamma (IFN- by the human NK 
cell line. The immunostimulatory effects of the IPs on the NK cells was assessed by the production 
of TNF- alone as IFN- was undetectable in our ELISA. In a cell death assay, the IPs were found 
to be non-toxic, without any observable evidence of early or late stage apoptosis within the NK92-
MI cells. Taken altogether, this novel class of synthetic peptides may prove to be a promising lead 
in the development of a new peptide-based immunotherapy approach, especially against B7H6 
expressing tumors. 
Alternatively, Pep42, a cyclic peptide selected from phage display bio-panning 
experiments, CTVALPGGYVRVC, has been shown to bind specifically to the heat shock family 
member Glucose-Regulated Protein 78 (GRP78) receptor, while internalizing poorly within tumor 
cells by receptor mediated endocytosis. GRP78 has been found to be exclusively overexpressed 
and cell surface localized on a variety tumor cells, where it promotes cancer initiation, proliferation 
vii 
 
and metastatic spread, but not on healthy tissue, making it a great biomarker for the development 
of targeted forms of cancer immunotherapy techniques. Moreover, Pep42, as a GRP78 ligand, has 
been conjugated to Taxol and pro-apoptotic peptide sequences, and used as a drug delivery vehicle 
triggering cell death selectively in in vitro and in vivo models.  
In an effort to identify novel therapeutic leads this thesis also describes the application of 
Pep42, its FITC-labeled derivatives, and a series of poly(ethylene glycol)-linked Pep42 sequences 
in tumor immunotherapy applications. The peptide sequences were accomplished by solid phase 
synthesis and some were modified with reactive N-succinimidyl carbamate linkages. Pep42 and 
its FITC-labeled derivatives have been tested for their capabilities to bind to the HepG2 human 
hepatocellular carcinoma cells. Flow cytometry revealed comparable binding of the synthetic 
peptides relative to the anti-GRP78 primary antibody at equal concentrations (100 nM). A blocking 
binding assay in between the human anti-NKp30 mAb or Pep42, and the specific N-20 GRP78 
peptide blocker showed similar blocking capabilities of either the primary antibody or Pep42, 
suggesting high specificity to GRP78.  In a cell death assay, Pep42 was found to be non-toxic. 
Moreover, the reactive N-succinimidyl carbamate derived peptides were envisioned to behave as 
reactive probes for their incorporation within bioactive proteins such as B7H6. Therefore, Pep42 
may prove to be a promising cancer targeting peptide for the development of immunostimulatory 
peptide-protein conjugates. Towards this ultimate goal, this thesis describes progress towards the 
design, development and application of novel semi-synthetic antibody mimics for NK-dependent 
treatment of tumors that overexpress GRP78 at the cell surface.  
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CHAPTER 1: INTRODUCTION 
Biological molecules that can trigger immune responses towards invading pathogens, 
allergens and cancer have led the advancement of immunotherapy.(1) Tumor immunotherapy 
involves the activation of white blood cells, either by stimulating lymphocytes ex vivo, followed 
by re-infusion of the activated cells into the patient. Alternatively, circulating tumor associated 
ligands in vivo can stimulate  inflammatory responses towards the destruction of the invasive tumor 
or blockage of pro-survival signals.(2-5) In an effort to promote in vivo stimulation of lymphocytes 
towards the eradication of tumors, treatment methods implicating cancer vaccines, tumor-
associated antigen derived small peptides (TAA-SP) or recombinant virus-like particles (VLP), 
cytokine therapy, and monoclonal antibodies (mAbs) have been developed and successfully 
administered in tumor immunotherapy applications.(1-7) (Figure 1.1) 
 
Figure 1.1. Immunological approaches to cancer therapy. Figure adapted from World J. 
Gastroenterol., 2014, 20, 1657-1666.3 
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1.3 IMMUNOSTIMULATORY PEPTIDES AND THEIR IMPACT ON 
IMMUNOTHERAPY 
Among the promising immunotherapy treatment regimes, the peptide-based TAA-SPs 
potentially encompass an underexplored yet promising class of immunostimulatory ligands that 
may have significant utility in clinical oncology. A brief survey of the current literature unveils a 
small set of short immunostimulatory peptides (IPs), commonly derived from the binding site 
interfaces in between the tumor associated ligand and its lymphocytic receptor, peptide epitopes 
which display multiple antigenic activity and isolated native sequences which exhibit 
immunomodulatory effects in vitro and in vivo.(8-18,35-39)  
For example, a new class of lipopeptides have been recently explored as agonists for the Toll-
like Receptor2 (TLR2) found on the cell surface of pancreatic tumors.(8) These peptides were based 
on the crystal structure analysis of the TLR2:ligand complexes in which the hydrophobic Cys(S-
[2,3-bispalmitoly)oxy-(R)-propyl] formed the minimal ligand binding site residue required for 
activity.(9,10) Variations were made to the remaining flexible peptide components by solid phase 
peptide synthesis (SPPS) to improve metabolic stability and immunostimulatory activity. From a 
series of thirteen modified lipopeptides, the Gly-D-Ser-PEGO-NH2 derived sequence 
demonstrated the most potent bioactivity (EC50: 20 nM) and the highest binding affinity (Ki: 25 
nM) within TLR2 overexpressing pancreatic tumor cells. The labeled sequence containing a near-
infrared (NIR) dye was used to track in vivo activity, which was maintained within TLR2 
overexpressing pancreatic mice xenografts. These studies elegantly demonstrated the ability of the 
IPs to bind selectively to the TLR2 and stimulate immunostimulatory activity of the antigen 
specific CD8+ T cells, which were capable of recognizing and killing the targeted tumor cells.  
3 
 
In a related example, a 20-amino acid MUC1 glycopeptide with a Gal-N-Ac-O-Thr residue was 
incorporated within a lead TLR ligand by a combination of solid phase glycopeptide synthesis and 
the azide-alkyne Huisgen cycloaddition reaction.(11) The latter facilitated conjugation of the 
palmitate-derived cysteine, Pam3Cys, residue to the glycopeptide sequence. A nanoparticle 
formulation was then prepared by combining L-rhamnose-cholesterol conjugates tethered to a 
tetra(ethylene)glycol linker with 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and the 
lead palmitate glycopeptide sequence. This nanoparticle formulation showed a >8-fold increase in 
antibody titers in comparison to the control mice groups that did not receive treatment. This 
nanoparticle formulation displayed active antigenic epitope components that may potentially serve 
as a cancer vaccine formulation.  
The multiple antigen presenting peptides (MAPs) have gained some of the most widespread uses 
in cancer vaccine applications.(12) Pioneered by Tam in the late 1980s to off-set the poor 
immunogenicity of single peptide vaccine units, the MAPs traditionally incorporated a Lys residue 
that was used for the introduction of multiple antigenic peptide epitopes which enhanced 
inflammatory responses.(13)  In a recent study, two B-cell and a T-cell epitope peptides were ligated 
by a maleimide-thioether conjugation strategy to afford the branched MAP system.(14) (Figure 1.2) 
The branched MAP displayed greater proteolytic stability, enhanced antibody titers and T cell 
stimulation over the linear peptide counterparts. The superior biological activity of the branched 
vs. linear peptides was attributed to the multiple antigen presentation which synergized 
inflammatory responses and enhanced resistance towards degradation which extended its duration 
of action. Most recently, Pachymodulin, a new hexapeptide sequence (SSLSKL) was isolated from 
the Mexican frog Pachymedusa dacnicolor and shown to favor leukocyte migration through the 
binding and activation of the N-formyl peptide receptor 2 (FRP2).(15) Migration of human 
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neutrophils, monocytes and T cells resulted from binding Pachymodulin (10 M) to FRP2, which 
stimulated a Gi protein coupled receptor (GPCR) signaling cascade that increased calcium flux, 
activated the mitogen-activated protein kinase (MAPK) and the extracellular regulated kinase 
(ERK) pathways. Inflammatory responses were also observed in vivo, upon peptide injections (40 
mg, three-times daily) in saline (150 mM) solution. Following 24 h post-treatment, the number of 
monocytes, macrophages and neutrophils were elevated in the peritoneal cavity and in the blood 
according to flow cytometry analyses relative to the saline treated control group. This new lead 
peptide may also exhibit promising immunotherapy responses within a tumor microenvironment.  
 
Figure 1.2. Multimeric presentation of peptidic epitopes targeting B and T cells, resulting in a 
peptide vaccine. Figure adapted from Bioconjug. Chem. 2013, 24, 578-585.14 
 
The discovery of the immunomodulator, prothymosin alpha (ProT) has been found to trigger 
potent anti-cancer responses by activating CD8+ T-cell lymphocytes.(16) Its immunostimulatory 
activity was found to be associated with the C-terminal decapeptide sequence, proT(100-109) 
which activated the TLR on antigen presenting tumor cells.(17) This peptide sequence (25 ng/mL) 
triggered cytotoxic K562 tumor cell line activity in vitro and a reduction in tumor volume in mice 
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xenografts due to immune responses which favored the stimulation and expansion of anti-cancer 
effector cells. Thus, IPs have been proven to be viable candidates in a variety of tumor 
immunotherapy approaches. This is based on their desirable pharmacological properties which 
includes, aqueous solubility, serum stability, potent immunogenicity and effective tissue 
penetration for in vivo activity.(18) 
It has been established that NK cells play a pivotal role in tumor detection and 
immunotherapy.(27-34) Representatively, the TAA-SP derived from the heat shock chaperone 
protein of 70 kilodalton (Hsp70) has been found to activate and expand NK cells towards potent 
tumor-targeted immunotherapy responses.(35,39) Peptide scanning revealed an N-terminal 14 amino 
acid sequence (TKDNNLLGRFELSG) capable of stimulating NK cell cytolytic activity at 10 
mg/mL.(35) Antibody and peptide blocking analyses identified CD94 as the activating NK cell 
receptor responsible for Hsp70 mediated cytolytic activity by granzyme B-mediated 
apoptosis.(36,37) Further in vivo studies demonstrated that after ex vivo stimulation of NK cells with 
the Hsp70 peptide and IL-2, reinfusion of the activated NK cells into Hsp70+ colon carcinoma 
bearing mice resulted in significant tumor weight reduction.(38)   Moreover, a phase I clinical trial 
validated that reinfusion of ex vivo stimulated human NK cells with a combination of Hsp70 
peptide and IL-2 into patients with colorectal and non-small cell lung cancer (NSCLC) was safe 
and well tolerated setting the stage for phase II clinical trials.(39) Thus, activated and expanded NK 
cells by the TAA-SP have proven to be a safe, well tolerated and clinically effective treatment 
regimen in cancer immunotherapy.  
 
1.4 B7H6: A PROMISING LIGAND FOR ACTIVATING NK CELLS FOR CANCER 
IMMUNOTHERAPY 
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1.4.1 NKp30: A MEMBER OF THE NCR FAMILY AND ITS ROLE IN 
IMMUNOSURVAILANCE AND NK CELL ACTIVATION 
Natural Killer (NK) cells are a class of cytotoxic lymphocytes that own the ability to rapidly 
eliminate transformed or infected cells upon activation and without prior sensitization.(19,20) It has 
been established that deficiencies in NK cell population, impaired expression or blocking of their 
activating receptors, gives rise to the spontaneous development of tumors and hematological 
malignancies.(21-23) Alternatively, infiltration of NK cells into tumors has been associated with 
potent cancer cell death effects and immunosurveillance which mitigates tumor recurrence and 
metastasis.(24-26) NK cells play a pivotal role in cancer immunosurveillance through recognition of 
major histocompatibility complex MHC class I molecules on target cells by inhibitory receptors 
of the KIR family, thus preventing NK cell activation.(40) NK cell activation requires the formation 
of a synapse between the NK cell and the target cells. This recognition site occurs when an 
inhibitory signal is absent, also known as recognition of ‘missing self’, in addition to the 
engagement of its cell surface expressed activating receptors.(41) (Figure 1.3) Activation of NK 
cell triggers the secretion of cytokines such as TNF- and IFN- and results in effective cytolytic 
activity against virus infected cells and transformed cells. NK cells also play a key role in maturing 
dendritic and pancreatic -cells.(42) For example, NK cells express a wide variety of activating 
receptors; including the natural-killer group 2 member D (NKG2D), the activating killer 
immunoglobulin-like receptors (KIRs),  DNAM-1, and the non-homologous Ig-like superfamily 
known as the natural cytotoxicity receptor family (NCRs), which includes NKp46 (NCR1, 
CD335), NKp44 (NCR2, CD336), and NKp30 (NCR3, CD337).(43)  Unlike other receptors, NCRs 
are expressed only on NK cells and contain multiple interaction sites within their ectodomains. 
These binding sites facilitate recognition of a variety of structurally different ligands, such as 
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HSPG, BAT3, MLL5.(44) Moreover, even when most of the NCR ligands are pathogen derived, 
reduced expression or blockage of the NCRs results in significantly reduced efficiency of 
malignant cell killing and increased resistance of cancerous cells. These combined effects suggests 
NCRs play a critical role in cancer immunosurveillance and antitumor activity.(45) All activating 
NCR signaling pathways require the association to an immunoreceptor tyrosine based activating 
motif (ITAM) bearing molecule.(46) (Figure 1.4) Upon association of the NCR to the adaptor 
protein in the corresponding transmembrane segments, SCR-family kinase-mediated 
phosphorylation of the tyrosine motifs within the ITAM molecule initiates a phosphorylation 
signaling cascade. This signaling pathway results in cytoskeletal reorganization, degranulation, 
secretion of cytokines and chemokines via Ca2+ flux, including IL-2, TNF-α, INF-γ, granzyme B 
and perforin which ultimately lead to NK -dependent malignant cell death (47,48,49)    
 
Figure 1.3. NK cell activation by recognition of “missing self”. Figure adapted from Nat. 
Rev. Immunol. 2007, 7, 329-339.25 
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Figure 1.4. Schematic representation of the NCR family members and their associated 
ligands. Figure adapted from Trends Immunol. 2013, 34, 182-191.47 
  
Importantly, NKp30 has been determined to be a dominant activating receptor involved in 
the lysis of various primary tumor cell lines by both, resting and activated NK cells.(41) The 30-
kDa activating receptor is a type I transmembrane protein, with an  extracellular IgV-like ligand-
binding domain that contains a short -helical stalk region, a transmembrane domain, and a short 
intracellular domain that lacks functionality.(42) Upon binding to its activating receptors, an 
arginine residue located in the transmembrane region of NKp30 associates with an aspartic acid in 
the ITAM adaptor protein domain,.(50) (Figure 1.5) When engaged with an inhibitory ligand, like 
the protein pp65 of HCMV and vaccinia virus haemagglutinin (HA), the transmembrane region of 
NKp30 dissociates form the CD3chain, resulting in NK cell inhibition and pathogen immune 
escape.(51) NK cells also engage in immunosurveillance through recognition of activating cellular 
derived ligands. NKp30 recognizes cell membrane localized antigens, like the BCL-2 associated 
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athanogene 6 (BAG6, also known as HLA-B- associated transcript 3 or BAT3) present on 
immature dendritic cells and stressed cells, heparin sulfate, and the recently discovered plasma 
membrane protein B7H6, expressed on malignantly transformed tumor cells and activated 
monocytes and neutrophils.(48-51) Thus, B7H6 has been found to play a pivotal role in tumor 
immunosurveillance and triggering the inflammatory response during infectious and/or malignant 
conditions.(48,52-54) The stalk domain and the glycosylation status of NKp30 modulates its ligand-
binding properties and regulates NK cells’ cytotoxicity.(55) Notably, a recent study revealed that 
the human NKp30 gene encodes six different variants, three of which produce V-type Ig 
extracellular domains (a, b, c).  In this case study, isoform a and b  transmit immunostimulatory 
TH1 cytokine production, and isoform c promotes immunosuppressive secretion of IL-10.
(56)  
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Figure 1.5. Schematic representation of NKp30 and the phosphorylation signaling pathway when 
bound to it cellular ligand B7H6. Figure adapted from Trends Immunol. 2013, 34, 182-191.47 
 
1.4.2 B7H6: A TUMOR LIGAND OF NKP30 
B7H6, a 51 kDa protein and member of the B7 family, was recently identified as a ligand 
of NKp30. Its sequence was revealed by chemical cross-linking studies, followed by tryptic 
digestion, tandem mass spectrometry and proteomic analyses of the leukemia cell line K562 with 
the soluble NKp30-Fc fusion protein.(57)  The transmembrane proteins of the B7 family, B7H6 
included, have two extracellular Ig domains encoded by exons with adjacent phase 1 introns. These 
sequences contribute to the regulation of the immune responses through co-stimulatory and co-
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inhibitory signals.(58) B7H6, is considered a tumor specific antigen because it was found to be 
constitutively expressed on the surface of malignantly transformed tumor cells but not on healthy 
cells. This observation has been confirmed experimentally by quantitative reverse transcription 
polymerase chain reaction QRT-PCR of B7H6 mRNA, gene microarray analysis, and protein 
expression of normal tissues and transformed tumor cells. (48)  The absence of B7H6 mRNA on 
normal tissues and its abundance on the surface of several tumor types, including T- and B-cell 
lymphomas, melanomas and carcinomas, suggests the expression is mediated by tumor 
transformation. (48) Moreover, it was recently reported that B7H6 evolved as a damage-associated 
molecular marker to initiate innate immunity against malignantly transformed or stressed cells.(59)   
Interestingly, the intracytoplasmic region of B7H6 contains various signaling domains, 
suggesting a role in response induction on NK cell targets. (49) The extracellular region of B7H6 
comprises two immunoglobulin-like domains with several potential N-glycosylation sites.(48) 
According to surface plasmon resonance (SPR) experiments between a recombinant Fc fusion 
form of B7H6 and NKp30, B7H6-Fc demonstrated binding to NKp30-Fc (KD = 1.0 ± 0.2 x10
-6 
M). No binding was detected with CTLA-4 or any other members of the CD28 family that share 
homology to NKp30, nor with any other NK cell-activating receptors. Additionally, no binding of 
NKp30-Fc with any other members of the B7 family could be detected, especially the closest B7H6 
homologs B7-H1 and B7-H3, suggesting selective binding between B7H6 and NKp30.( 48,57) 
Moreover, the binding interactions in between the soluble B7H6-Fc with the NKp30-Fc fusion 
protein were abolished in the presence of the anti-NKp30 mAbs (1849 and AZ20), known to block 
NKp30-dependent cell activation.(48)  Furthermore, murine T cells expressing a chimeric receptor 
of NKp30 fused with CD3 were capable of secreting IL-2 upon exposure to B7H6 expressing 
cells, but not when exposed to B7H1 expressing cells. The levels of IL-2 were significantly 
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reduced when in the presence of blocking anti-NKp30 mAb F(ab’)2 or B7H6 antiserum. 
Additionally, these B7H6 expressing cells were susceptible to cytolysis by primary NK cells and 
the human derived NK-92 cell line, and this effect was abolished in the presence of soluble NKp30-
Fc.(48) Additionally, downregulation or shedding of B7H6 on tumor cells was shown to reduce 
NKp30 dependent effector functions of the NK cells.(60,63) Interestingly, neither B7H6 nor NKp30 
orthologues exist in mice.(59) 
 
1.4.3 B7H6 BINDING INTERACTION WITH NKp30 
As a member of the B7 family, B7H6 is composed of distal N-terminal V-like domains and 
a proximal C-like domain, where the N-terminal is sufficient for NKp30 recognition.(61) The V-
like domain of B7H6 contains two antiparallel -sheets, two potential N-glycosylation sites, and 
the NKp30 receptor binding site. The active site is located at the front -sheet where amino acid 
residues located in the GFCC’ strand and loops BC, C’C” and FG engage in receptor binding. The 
crystal structure analyses of the B7H6:NKp30 binding interface also revealed a 1:1 ligand:receptor 
stoichiometry in an antibody-type structure. (57) This stable complex is based on twelve NKp30 
amino acid residues bound to eleven B7H6 residues through predominantly stable hydrophobic 
interactions. These non-covalent bonding interactions are complimented by 16 van der Waals 
contacts (Thr127 and Pro128 in B7H6), 2 hydrogen bonding interactions (B7H6 Thr127 O-N 
NKp30 Gly51 and B7H6 Pro128 O-N NKp30 Val53) and one salt bridge (B7H6 Lys130 N-O 
NKp30 Glu113), with no bound water at the binding interface.(57) (Figure 1.6) Shape correlation 
statistic calculations demonstrated that the binding interface is characterized by high-shape 
complementarity (Sc value of 0.77), characterized also by the exclusion of bulk solvent.
 (57) 
Furthermore, superposition of the V-like domain of the bound and un-bound form of B7H6 to 
13 
 
NKp30 demonstrated structural adjustment of the C’C”, BC and FG loops of B7H6 to avoid steric 
hindrance, as well as a shift in B7H6 Gly83 towards NKp30 active site for binding contact. 
Ultimately, these interactions contributed to selective B7H6:NKp30 binding and activation of NK 
cells. In spite of its immunostimulatory activity, B7H6 retains moderate NKp30 binding affinity, 
limited stability and bioavailability which hinders its therapeutic efficacy. (57) 
 
Figure 1.6. The NKp30-B7H6 binding interface. A) Docking mode of NKp30 (green) bound to 
B7H6 (yellow), B) Stereo view of NKp30 (green) bound to B7H6 (orange) with interacting 
residues in ball and stick representation, C) NKp30 molecular surface (grey) bound to residues 
125-130 of the FG loop of B7H6 in stick format. Figure adapted from J. Exp. Med. 2011, 208, 
703-714.57 
 
1.4.7 APPLICATIONS IN CANCER IMMUNOTHERAPY 
As a cancer cell biomarker, B7H6 could be an interesting target for selective NK-cell 
mediated immunotherapy approaches with a comprehensive understanding of the biological 
mechanisms underlining its modulation.  Recently, it was discovered that the class I-specific 
histone deacetylases inhibitors (HDACi), regulate gene expression by inhibiting enzymes that 
remove acetyl groups in the promoter regions of histone and non-histone proteins, causing 
downregulation of B7H6 expression on hematological and solid tumors.(60)  Additionally, qRT-
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PCR and protein expression studies, along with pharmacological inhibition of transcription factors 
(TFs) associated with tumorigenesis, revealed that regulation of B7H6 expression in tumor cells 
is related to the proto-oncogene Myc. Myc proteins in complex with Myc-associated factor X 
(Max), bind to defined DNA sequences (enhancer boxes, E-boxes) and activate transcription of 
certain target genes.(62) Silencing of c-Myc or N-Myc led to downregulation of B7-H6 on many 
primary tumors, including hepatocellular carcinomas, lymphomas and neuroblastomas. Therefore, 
targeting B7H6 could be a promising target for NK cell mediated immunotherapy on Myc-driven 
tumors. 
Furthermore, a study for posttranscriptional modifications regulating B7H6 expression on 
tumor cells revealed that some tumors express comparably high levels of B7H6 mRNA but low 
protein levels on the cell membrane (Figure 1.7).(63) According to Western blot and ELISA 
analyses of concentrated supernatants of different types of harvested tumor cell cultures; the 
glycosylated ectodomain of B7H6, containing an N-terminal myc-tag, was found to be released 
from the cell surface of tumor cells.(63) Moreover, reduced levels of soluble B7H6 in concentrated 
supernatants of tumor cell cultures incubated with batimastat or G1254023X, two metalloprotease 
inhibitors. Alternatively, elevated surface levels of B7H6 was detected in cells transfected with 
different metalloprotease siRNAs, suggested proteolytic shedding driven by the metalloproteases 
“a disintegrin and metalloproteases” ADAM-10 and ADAM-17.(63) Finally, soluble B7H6 is not 
responsible for modulating the expression of the corresponding receptor on NK cells. This was 
demonstrated by surface expression of NKp30 in NK92-CI cells incubated in concentrated 
supernatant of tumor cells. Upregulation of membrane B7H6 expression improved recognition and 
degranulation of NK92-CI cells.(63)  
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Figure 1.7. Analysis of a) B7H6 mRNA and b) B7H6 cell surface expression on different tumor 
cell lines. Figure adapted from: Cancer Res., 2014, 74, 3429-3440.63 
 
In an effort to develop new B7H6 derived immunotherapy methodologies, a novel 
immunoligand composed of a recombinant fusion protein of a CD20-specific single chain 
fragment variable (scFv) and the extracellular domain (ECD) of B7H6, namely B7H6:7D8, was 
successfully expressed in eukaryotic cells, deglycosylated and purified by affinity chromatography 
(Figure 1.8).(64) The immunoligand  B7H6:7D8 demonstrated the ability to crosslink CD20+ 
cancer cells with NK cells. This binding interaction resulted in activation and degranulation of NK 
cells as measured by the expression of the early inducible activation marker CD69, surface 
exposure of the degranulation marker CD107a (LAMP-1), and production of the inflammatory 
cytokines TNF- and IFN-.(64) The binding activity of the immunoligand was confirmed by flow 
cytometry which demonstrated exclusive binding to CD20 presenting tumor cells, and to the 
soluble NKp30-Fc receptor.(64) Alternatively, genetically modified primary T-cells with a tumor 
targeting chimeric antigen receptor (CARs) composed of the extracellular domain of NKp30 
(chNKp30), fused to the transmembrane and signaling domains of CD3, have been developed.(65) 
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The chimeric NKp30 transduced human T cells responded to B7H6+ tumor cells, resulting in 
measurable responses of INF- secretion which ultimately resulted in tumor cell death. (65) 
 
Figure 1.8. Ribbon structure of the recombinant B7H6:7D8. Figure adapted from: J. 
Immunol., 2012, 189, 5037-5046.64 
 
1.5 Pep42: A GRP78 SELECTIVE PEPTIDIC LIGAND  
The discovery of peptide ligands, and their cyclic analogs, that can selectively target cancer 
cells have led to more efficient delivery of drug payloads while reducing the harmful side effects 
in cancer patients.(66,67) In an effort to identify novel peptidic ligands, a series of cyclic peptides 
generated by the phage-display bio-panning methodology was proven successful for the isolation 
of peptidic ligands which targeted and penetrated human melanoma Me6652/4 tumor cells.(68) 
DNA sequencing of the bound phages revealed that a 13-mer cyclic peptide, composed of 
CTVALPGGYVRVC-CONH2 and designated Pep42, bound selectively to Me6652/4 tumor cells 
(Figure 1.9).(69) Interestingly, confocal laser scanning microscopy and flow cytometry analyses of 
the fluorescently labeled Pep42 sequence revealed that the cyclic Pep42, but not its linear structure, 
bound and internalized selectively in cancer cells through receptor-mediated endocytosis.(69) 
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Additional photoaffinity cross-linking and antibody uptake inhibition studies identified the glucose 
regulated protein of 78 kilodaltons (GRP78), as the cancer cell surface membrane expressed 
receptor responsible for selective binding and internalization of Pep42.(69) Interestingly, Pep42 
binds to recombinant GRP78 but not to recombinant HSP70, another member of the HSP family 
that shares a high degree of sequence homology.(70) Furthermore, flow cytometry and photoaffinity 
labeling studies on HepG2 and HDFa cells revealed that Pep42 binds selectively to cell surface 
localized GRP78 on primary tumor cells. The binding was significantly diminished in the presence 
of the blocking anti-GRP78 polyclonal antibodies or when cells were treated with GRP78-specific 
siRNA for gene knockdown. This studies confirmed GRP78 as the cancer-cell molecular target for 
the peptidic ligand Pep42.(68,69) The capability of Pep42 to induce cancer-cell targeted cytotoxicity 
was evaluated in vitro using a Pep42 derivative conjugated to an apoptosis-inducing peptide, D-
(KLAKLAK)2. Pep42-D-(KLAKLAK)2-mediated cytotoxicity was dependent on the cell surface 
expression of GRP78 and was significantly reduced when GRP78 expression was downregulated 
with GRP78 siRNA.(69) More importantly, Pep42 has significant tumor homing capabilities in vivo, 
as revealed in studies with xenograph mice, highlighting the promising capabilities of Pep42 as a 
cancer targeted drug-delivery vector.(69)  
 
Figure 1.9. Sequence of Pep42 and GRP78 specificity within Me6652/4 tumor cells. 
Figure adapted from: Biochemistry, 2006, 45, 9434-9444.68 
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In normal cells, the 78 kDa member of the heat shock family HSP70 namely GRP78, is 
localized in the endoplasmic reticulum (ER). It plays a key role as an intracellular chaperone 
protein regulating protein folding events as part of the unfolded protein response (UPR), thus 
mediating protective cellular responses during stress conditions.(70) Interestingly, under malignant 
transformation, GRP78 is overexpressed and cell membrane localized in cancer cells, where it 
exhibits a pivotal role in tumor initiation, progression, metastatic events, and drug resistance.(71-
73,) More importantly, GRP78 has been found to be expressed in plasma membrane of cancer cells 
but not in normal cell, thus making it a good target for selective cancer therapy approaches.(74,75)  
 
1.6 THESIS RESEARCH OBJECTIVES 
1.6.4 B7H6 DERIVED PEPTIDES 
 B7H6 was recently discovered as a cell surface protein uniquely expressed in tumor cells. 
B7H6 is also a ligand for NKp30, a receptor expressed constitutively on all resting and activated 
NK cells. Upon B7H6-NKp30 binding, B7H6 triggers NKp30 dependent NK cell activation, 
resulting in the release of cytokines and chemokines that ultimately leads to tumor cell lysis and 
death. In an effort to develop novel and effective immunotherapy approaches, the rational design, 
synthesis, characterization and biological evaluation of a novel class of immunostimulatory 
peptides (IPs) is described in Chapter 2.   
Towards this goal, the rational design of a small library of synthetic peptides derived from 
the crystal structure analysis of the B7H6-NKp30 binding interface is described.   The 
methodology for the Fmoc-based solid phase peptide synthesis, the introduction of fluorescent tags 
(FITC), and the characterization methodologies of the library of peptides by LCMS, RP HPLC, 
and CD spectroscopy, are also outlined. 
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With pure peptides in hand, analyses of the binding interactions of the synthetic FITC 
labeled peptides for the NKp30 receptor expressed on the surface of NK92-MI cells were 
accomplished by flow cytometry. The capabilities of the non-labeled peptides to induce NK92-MI 
cells’ immunostimulatory responses was also assessed via the release of the inflammatory 
cytokines, TNFα and INFγ by an enzyme-linked immunosorbent assay (ELISA). Moreover, the 
cytotoxicity of the synthetic peptides was also evaluated by flow cytometry, to determine the 
therapeutic applicability of the IPs. 
 
1.6.5 Pep42 DERIVED PEPTIDES 
Chapter 3 of this thesis describes the relevance of Pep42 and its biological activity on the 
GRP78 overexpressing HepG2 liver cancer cells. These experiments have served to validate the 
HepG2 cells as a good model cell line to test the biological activities of the Pep42 derived peptides. 
The optimized Fmoc-solid phase synthetic methodology of Pep42 and the characterization 
methodologies using LC/MS and RP-HPLC are outlined and described in this chapter. Also 
described are orthogonal synthetic methods for Pep42 activation for bio-conjugation onto bio-
active proteins such as B7H6. Moreover, the relevance of the Pep42 secondary structures, 
determined by CD spectroscopy, on their biological activity is also highlighted in this chapter. 
   
1.6.6 B7H6-Pep42 DERIVED BIOCONJUGATES 
Tumor associated antigens (TAAs) are a class of protein biologics that are rapidly emerging 
in cancer immunotherapy strategies. Characteristically, B7H6 has been identified as a TAA 
uniquely localized on the cell surface of transformed cells. B7H6 binds selectively to the NKp30 
receptor, a family member of the NCRs located on resting and activated NK cells. It was also 
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recently discovered that tumor cells escape immunosurveillance by shedding B7H6, therefore 
impeding NK-mediated recognition and activation. To overcome this resistance mechanism, the 
development of new B7H6 derived ligands that may effectively target NKp30 and activate NK 
cells towards B7H6 deficient tumors is proposed in Chapter 4 of this thesis. In this new 
immunotherapy approach, a novel class of B7H6-Pep42 derived cancer-targeting 
immunostimulatory protein-peptide conjugates (CTIPPC) that may potentially mimic the targeting 
and effector functions of antibodies is described.  
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CHAPTER 2: THE DISCOVERY OF B7H6-DERIVED IMMUNOSTIMULATORY 
PEPTIDES OF LYMPHOCYTIC NK92-MI CELLS 
2.1. ABSTRACT 
The rise of biologics that can stimulate immune responses towards the destruction of 
tumors has led to the advancement of cancer-based immunotherapy. B7H6 has been recently 
identified as an immunostimulatory protein ligand on tumor cells that binds specifically to the 
NKp30 receptor. Upon binding, NKp30 activation triggers NK cell-derived cytokine release, 
which ultimately leads to tumor cell lysis and death. In an effort to develop effective 
immunotherapy approaches, the rational design of a novel class of immunostimulatory peptides 
(IPs) derived from the binding interface of B7H6:NKp30 is described in this chapter. The IPs are 
composed of the B7H6 active site sequence for NKp30 binding and immunostimulatory activity. 
An aminohexanoic acid linker was also introduced at the N-terminus of the peptides for FITC-
labeling by Fmoc-solid phase peptide synthesis. The peptides were characterized by LCMS to 
confirm identities and purities >95%. The secondary structures of the peptides were evaluated by 
CD spectroscopy in H2O, PBS and a H2O:TFE mixture which demonstrated flexible peptide 
structures which adapted to the solvent conditions and were found to transition from random coil 
(H2O) to -helical (PBS) and turn-type (H2O:TFE) conformations. Their biological properties 
were then evaluated by flow cytometry, enzyme-linked immunosorbent assays (ELISAs) and cell 
death assays. The occupancy of the synthetic peptides to a human NK cell line resulted in 
comparable binding relative to the natural NKp30 ligand, B7H6, and the human anti-NKp30 
monoclonal antibody (mAb), in a concentration dependent manner. A competitive binding assay 
in between the human anti-NKp30 mAb or B7H6, and the synthetic peptides, demonstrated partial 
displacement of the ligands upon anti-NKp30 mAb treatment, suggesting specific NKp30 receptor 
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binding by the synthetic peptides. Moreover, the immunostimulatory activity of B7H6 was 
demonstrated by the secretion of the pro-inflammatory cytokines, tumor necrosis factor-alfa (TNF-
 and interferon gamma (IFN- by the human NK cell line. The immunostimulatory effects of 
the IPs on the NK cells was assessed by the production of TNF- alone as IFN- was undetectable 
in our ELISA. In a cell death assay, the IPs were found to be non-toxic, without any observable 
evidence of early or late stage apoptosis within the NK92-MI cells. Taken altogether, this novel 
class of synthetic peptides may prove to be a promising lead in the development of a new peptide-
based immunotherapy approach, especially against B7H6 expressing tumors. 
 
2.2. INTRODUCTION 
Natural Killer (NK) cells are a class of cytotoxic lymphocytes that own the ability to rapidly 
seek and destroy transformed or infected cells upon activation or without prior sensitization.(1,2) It 
has been established that deficiencies in NK cell population, impaired expression or blocking of 
their activating receptors, gives rise to the development of tumors and blood disorders.(3-5) 
Alternatively, infiltration of NK cells into tumors has been associated with potent cancer cell death 
effects and immunosurveillance which minimizes tumor recurrence and metastasis, even in the 
absence of a functional adaptive immune system.(6-8) Therefore, it has been established that NK 
cells play an important role in tumor detection and immunotherapy.(9-16) Their biological and 
therapeutic functions are based on a series of activating NK cell receptors. These include the 
natural-killer group 2 member D (NKG2D), activating KIRs, NKp80, CD94/NKG2C, DNAX 
accessory molecule (DNAM)-1, 2B4, and the transmembrane immunoglobulin-like natural 
cytotoxicity receptors (NCRs) NKp30, NKp44, and NKp46.(17,18) Representatively, the NKp30 
receptor is a key mediator of NK cell immunostimulatory activity, and is expressed constitutively 
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on resting and activated NK cells. Activation of the NKp30 receptor stimulates the secretion of 
pro-inflammatory cytokines and chemokines, and the release of cytotoxic agents such as 
membrane disrupting proteases that trigger tumor cell lysis and death.(19) Thus, activated NK cells 
have effectively formed a first line of defense against a wide range of human tumor malignancies 
leading towards their successful clinical applications in cancer immunotherapy.  
In the search for activating NKp30 ligands, chemical cross-linking studies followed by 
tryptic digestion, tandem mass spectrometry and proteomic analyses of the leukemia cell line K562 
with the soluble NKp30-Fc fusion protein revealed B7H6 as a cellular membrane expressed protein 
ligand of the NKp30 receptor.(20) B7H6 is a 454 amino acid (51 kDa) type I transmembrane protein 
with an extracellular domain implicated in NKp30 binding and a cytosolic region that is 
homologous to the GAG polyprotein and involved in signaling activity.(21) Interestingly, B7H6 
was found to be expressed on the surface of tumors but not on healthy cells and functions as a bio-
marker for NK cell mediated cytotoxicity.(21) In a direct binding assay, B7H6 was found to bind 
specifically to the NKp30 receptor according to surface plasmon resonance (SPR) (KD = 1.0 ± 0.2 
x10-6 M).(20,21) Moreover, the binding interactions in between the soluble B7H6-Fc with the 
NKp30-Fc fusion protein were inhibited in the presence of the anti-NKp30 mAbs (1849 and 
AZ20), known to block NKp30-dependent cell activation.(21) Furthermore, downregulation of 
B7H6 on tumor cells was shown to reduce NKp30 dependent effector functions of the NK cells.(22)  
It has been previously described that upon binding to its activating ligand, a transmembrane 
arginine charged residue of NKp30 associates to a negatively charged transmembrane residue of 
an immunoreceptor tyrosine based activation motif (ITAM)-containing adaptor protein. This 
includes  the disulfide linked homodimers of CD3ζ, which initiates the signaling cascade.(18,21,23) 
The latter results in the reorganization of the NK cells’ cytoskeleton and initiation of Ca2+ flux, 
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that leads to the secretion of inflammatory cytokines such as IL-2, TNF-α, INF-γ, as well as the 
release of granzyme B and perforin, which trigger tumor cell lysis and death.(19,24,25) The crystal 
structure analyses of the B7H6:NKp30 binding interface also revealed a 1:1 ligand:receptor 
stoichiometry. This stable complex was based on twelve NKp30 amino acid residues bound to 
eleven B7H6 residues through predominantly stable hydrophobic interactions, complemented by 
van der Waals contacts, hydrogen bonding and salt bridges.(20) These interactions contributed to 
selective B7H6:NKp30 binding and activation of NK cells. In spite of its immunostimulatory 
activity, B7H6 exhibits moderate NKp30 binding affinity, limited stability and bioavailability 
which hinders its therapeutic efficacy. 
However, the discovery of the B7H6:NKp30 binding interaction offers a new opportunity 
in the development of novel NK cell-dependent immunostimulatory ligands. In this study, the 
design, synthesis and biological evaluation of short peptidic ligands derived from the 
B7H6:NKp30 binding domain are reported. This new class of IPs may have a potential impact in 
tumor immunotherapy applications, while overcoming some of the limitations of the high 
molecular weight biologicals, such as B7H6 or the monoclonal antibodies.  
 
2.3. PROJECT OBJECTIVES 
The main effort of this research project is related to the rational design, synthesis, structure 
characterization, and biological activity of a new class of immunostimulatory peptides (IPs). This 
research project will be completed by the following objectives. 
 
2.3.1. RATIONAL DESIGN   
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The crystal structure analysis of the B7H6:NKp30 binding interface revealed 11 amino 
acids on B7H6 responsible for the binding and activation of the NKp30 receptor.(20) The design of 
a small library of immunostimulatory peptides was derived from the B7H6 primary sequence and 
secondary structure amino acid residues that bound to the active site of NKp30. Molecular docking 
studies will provide further insight into the binding capabilities of this new class of synthetic 
peptides.      
 
2.3.2. SYNTHESIS AND CHARACTERIZATION  
The Fmoc solid phase peptide synthesis (Fmoc-SPPS) method will be employed for the 
rapid production of the immunostimulatory peptide sequences. Furthermore, this conventional 
synthetic method may also facilitate the introduction of fluorescein isothiocyanate (FITC) for 
biological studies. Following peptide synthesis, LCMS will be used to analyze and confirm the 
identities of the peptides by molecular weight analyses. Peptide purification will be completed by 
semi-preparative RP HPLC. Circular dichroism spectroscopy will be employed to determine the 
secondary structures, if any, adopted by the synthetic peptides in a variety of solvent systems. 
 
2.3.3. IN-VITRO BIOLOGICAL ACTIVITY  
The binding affinity and specificity of the library of FITC labeled immunostimulatory 
peptides to NKp30 expressed on NK92-MI cells will be assessed via flow cytometry. Upon binding 
determination, the capability of the non-labeled peptides to induce an immune response of NK92-
MI cells will be assed via the release of TNFα and INFγ. The release of the inflammatory cytokines 
will be evaluated by an enzyme-linked immunosorbent assay (ELISA). The toxicity of these 
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synthetic peptides to NK92-MI cells will be assessed by determination of apoptotic events using a 
Guava Nexin® Reagent.   
 
2.4. RESULTS 
2.4.1. DESIGN OF B7H6-DERIVED PEPTIDES. 
The rational design of the synthetic peptides was based on the crystal structure of the 
binding interface of the B7H6:NKp30 ligand:receptor.(20) Residues 125-130 of the FG loop region 
of B7H6 (VTPLK, 3) facilitated binding to its receptor by means of sixteen Van der Waals contacts 
with NKp30 residues. Additionally, two hydrogen bonds (B7H6; Thr127 and Pro128 with NKp30; 
Gly51 and Val53, respectively) and a salt bridge interaction (B7H6; Lys130 with NKp30 Glu111) 
contributed to the B7H6:NKp30 binding interaction.(20) Residues 59-62 (TSMG, 2) found within 
the BC loop region and 82-83 (FG, 1) located in the C’C” region of B7H6 complement NKp30 
binding predominantly through Van der Waals contacts.(20) The peptide (FGTSMGVTPLK, 4) was 
selected based on the primary sequence of B7H6 which bound to the active site of NKp30. 
Whereas peptide (TSMGFGVTPLK, 5) was based on the residues bound in the secondary structure 
of B7H6, which adopted a turn-type geometry at the active site of the NKp30 receptor.(20) Finally, 
a modified sequence was rationally designed to enhance the binding interactions with NKp30. The 
peptide (TVPLN, 6) was derived from the binding site FG loop region of B7H6, but with exchange 
of the N-terminal Thr and Val, and replacement of the C-terminal Lys for Asn. These modifications 
were rationalized to enhance hydrogen bonding and to stabilize the putative turn conformation 
which contributed to binding in between the B7H6 ligand and the NKp30 receptor.(20) In a 
molecular docking study in between peptide 6 and the NKp30 binding pocket the turn 
conformation and H-bonding interactions with the NKp30 Gly51 and Val52 were found to be 
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conserved (Figure 2.1).  The designed peptide sequences also contained an aminohexanoic acid 
(Ahx) linker at the N-terminus to facilitate the incorporation of a fluorescein isothiocyanate (FITC) 
for biological studies (Table 2.1, sequences 7-12).  
 
Figure 2.1. Molecular docking studies of peptide 6 bound to the NKp30 binding pocket. (A) 
Hydrogen bonding interactions between peptide 6 and NKp30 residues Gly51 and Val53 shown 
as dotted lines. The interacting residues are shown in ball and stick representation. NKp30 
interacting residues are labeled and shown in green. Peptide 6 carbon atoms shown in cyan, 
nitrogen atoms in blue and oxygen atoms in red.  (B) NKp30 molecular surface is shown in grey 
with the region containing the binding site for B7H6 colored in wheat. Peptide 6 shown in ball and 
stick representation. 
 
2.4.2. SOLID PHASE PEPTIDE SYNTHESIS 
   The synthesis of the peptides was accomplished by conventional Fmoc-based solid phase 
peptide synthesis on a Rink amide linker hydrophilic poly(ethylene glycol) resin (NovaPEG, 
0.52mmol/g).(26,27) Peptides 1-6 were further labeled with FITC to obtain peptides 7-12 for their 
use in biological studies (Figure 2.2). Peptides were recovered in crude yields (19-88%) and 
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purities (13-95%) according to RP HPLC. Synthetic peptides, 1-12, were further purified by semi-
preparative RP HPLC and isolated in purities ≥93%, and yields (10-44%) for structure-activity 
relationship studies. The identities of the synthetic peptides 1-12 were confirmed by mass 
spectrometry which validated sequence composition based on mass/charge ratios (Table 2.1).  
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Table 2.1. Characterization of the synthetic peptides derived from the B7H6:NKp30 binding 
interactions.
 
 
2.4.3. CIRCULAR DICHROISM SPECTROSCOPY 
A circular dichroism study in the far-UV region (190-280 nm) was conducted to determine 
the secondary structures (if any) adopted by the peptides (3-6).(28,29) The selected peptides were 
dissolved in water, phosphate buffered saline (PBS), or a mixture of 2,2,2-trifluoroethanol:water 
(TFE:H2O, 50:50 v/v) at constant samples concentrations (40 M) to analyze the influence of the 
solvent on peptide structure. All peptides showed different conformations that were dependent on 
the solvent system (Figure 2.3). The peptides (3-6) showed a CD signature characteristic of a 
random coil when dissolved in water, with the distinctive minimum band near 200 nm (Figure 
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2.3.A). In PBS, the peptides 3-6 were found to transition from random coils into helical type 
structures, with representative minimum bands near 210 and 220 nm and a maximum near 190 nm 
(Figure 2.3.B). Moreover, the peptides 3-6 adopt turn type conformations when dissolved in the 
TFE:H2O mixture, as seen by the typical negative bands near 200 and 230 nm and maxima near 
210 and 260 nm, (Figure 2.3.C). Interestingly, peptide 5, was found to display a unique reverse 
turn geometry which opposed that of the remaining peptides (3, 4 and 6) with a broad minimum 
band observed in between 240-260 nm, another near 190 and 210 nm, and maximum peaks 
observed near 200 and 220 nm.   
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Figure 2.3. Circular dichroism spectra of peptides 3-6 (40 mM) in: A) water, B) PBS, and C) TFE: 
H2O (50:50, v/v). Data representative of three independently conducted experiments. 
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2.4.4. DIRECT BINDING STUDIES ON THE NK92-MI CELLS. 
In order to evaluate the ability of the FITC-labeled synthetic peptides, 7-12, to bind to the 
cell surface of NK cells, the human NK cell line, NK92-MI, was incubated for 30 minutes with 
the peptides, 7-12, at various concentrations (0.1, 1, 10 M) in PBS. Their binding capabilities 
was compared to that of the natural ligand, soluble B7H6-Fc (1 M), and the anti-NKp30 APC 
labeled mAb (2 g/ml) (Figure 2.4.A). Flow cytometry revealed comparable NK cell occupancy 
(80-97%) between the anti-NKp30 mAb, B7H6, and all the FITC-labeled peptides, 7-12, at a 
peptide concentration of 10 M (Figure 2.4.B). Moreover, the peptides, were found to display 
dose-dependent binding on the NK cells, with optimal binding values (80-97%) observed at 10 
M, moderate binding (24-50%) at 1 M and minimal binding at 0.1 M (3-4%). 
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Figure 2.4. Direct binding studies with the NK92-MI cells. (A) Figurative representation of the 
NK cells’ binding in between the anti-NKp30 mAb, B7H6 and the FITC-labeled peptides, 7-12. 
(B) Flow cytometry analyses of the NK92-MI cells’ binding with anti-NKp30 mAb (2 g/mL, 2 
L), B7H6 (1 M, 50 L) and the FITC-labeled peptides, 7-12, (0.1-1 M, 50 L) in PBS. Data 
representative of three independently conducted experiments. 
 
2.4.5. CONCENTRATION DEPENDENT BINDING OF B7H6. 
In an effort to confirm that the observed fluorescent signal of soluble FL-B7H6-Fc (1 M, 
50 l) was due to the binding capabilities of B7H6-Fc with NKp30-Fc and not a result of a 
saturated signal, the human NK cell line, NK92-MI, was incubated for 30 minutes with soluble 
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FL-B7H6-Fc (1 M, 20 l and 50 l) and the anti-NKp30 APC labeled mAb (2 g/ml) (Figure 
2.5). Flow cytometry assays revealed equal binding capabilities of B7H6-Fc on NK cells despite 
the varying amounts of sample, (50 mol and 20 mol, 74.6-80.6%) and comparable to anti-
NKp30 mAb (94.8%). 
 
Figure 2.5. Direct binding studies with the NK92-MI cells. (A) Figurative representation of the 
NK cells’ binding in between the anti-NKp30 mAb and B7H6. (B) Flow cytometry analyses of the 
NK92-MI cells’ binding with anti-NKp30 mAb (2 g/mL, 2 L) and B7H6 (1 M, 20 and 50 L), 
in PBS. 
 
2.4.6. COMPETITIVE BINDING STUDIES ON THE NK92-MI CELLS. 
A competitive binding assay was conducted in between the FITC-labeled peptides, 7-12, 
and the NKp30 ligands, Alexa Fluor 488-labeled B7H6 and the APC-labeled anti-NKp30 mAb 
(clone 210845, R&D systems) in order to evaluate NKp30 binding specificities (Figure 2.6.A). In 
this assay, the NK92-MI cells were initially incubated for 30 minutes with either the Alexa Fluor 
488-labeled B7H6 ligand (1 M) or the FITC-labeled peptides, 7-12 (10 M), followed by a 30 
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minute treatment with the APC-labeled anti-NKp30 mAb (2 g/ml). Flow cytometry revealed 
partial displacement of the Alexa Fluor 488-labeled B7H6 ligand (69%) and the peptides, (6-35%) 
upon APC-labeled anti-NKp30 mAb treatment (Figure 2.6.B).  
In a complementary competitive binding assay, the NK92-MI cells were incubated first 
with the APC-labeled anti-NKp30 mAb (2 g/ml), followed by treatment with either the Alexa 
Fluor 488-labeled B7H6 ligand (1 M) or the FITC-labeled peptides, 7-12, (10 M) (Figure 
2.7.A). No displacement of the mAb or blocking of the ligands, B7H6 and peptides, for the NK 
cells was observed. In this case, the NKp30 ligand B7H6 and the synthetic peptides maintained 
stable binding (80-84%) to the NK cells with and without prior treatment of the anti-NKp30 mAb 
(Figure 2.7.B).   
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Figure 2.6. Competitive binding studies with the NK cells. (A) Figurative representation of the 
competitive binding studies in between fluorochrome-labeled B7H6, peptides, 7-12, and the anti-
NKp30 mAb. (B) Flow cytometry of the direct vs. competitive binding of Alexa Fluor 488-labeled 
B7H6 (1 M, 20 L PBS) and the FITC-labeled peptides, 7-12, (10 M, 50 L PBS) without and 
with successive treatment of the APC-labeled anti-NKp30 mAb (2 g/mL, 2 L) on the NK92-MI 
cells. Data representative of three independently conducted experiments. 
 
 
 
Figure 2.7. Complementary competitive binding studies with the NK cells. (A) Figurative 
representation of the fluorochrome-labeled anti-NKp30 mAb binding of the NK cells followed by 
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treatment with B7H6 and the peptides, 7-12. (B) Flow cytometry analyses of the direct vs. 
competitive binding of Alexa Fluor 488-labeled B7H6 (1 M, 20 L PBS) and the FITC-labeled 
peptides, 7-12, (10 M, 50 L PBS) without and with prior treatment of the APC-labeled anti-
NKp30 mAb (2 g/mL, 2 L) on the NK92-MI cells. Data representative of three independently 
conducted experiments. 
 
2.4.7. COMPETITIVE BINDING STUDY BETWEEN B7H6-FC AND THE B7H6-
DERIVED PEPTIDES. 
A competitive binding assay was conducted in between the FITC-labeled peptides, 7-12, 
and the NKp30 ligand, soluble B7H6-Fc to evaluate NKp30 binding specificities of the FITC-
labeled peptides (Figure 2.8). In this assay, the NK92-MI cells were initially incubated for 30 
minutes with the B7H6 ligand (1 M) followed by a 30 minute treatment with the FITC-labeled 
peptides, 7-12 (10 M). Flow cytometry revealed efficient binding occupancy of the peptide 
ligands (>99%) with B7H6-Fc pre-treatment (Figure 2.8).  
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Figure 2.8. Competitive binding studies with the NK cells. (A) Figurative representation of the 
competitive binding studies in between soluble B7H6-Fc and B7H6 derived peptides, 7-12. (B) 
Flow cytometry of the blocking experiment the FITC-labeled peptides, 7-12, (10 M, 50 L PBS) 
with pre-treatment with soluble B7H6 (1 M, 20 L PBS) on the NK92-MI cells. Data 
representative of three independently conducted experiments. 
 
2.4.8. SYNTHESIS OF NEGATIVE CONTROL PEPTIDES 
To further assess the specific activities of the B7H6 derived peptides (1-6), a series of non-
specific control peptides (13-16) were also synthesized by Fmoc-SPPS and isolated by LCMS. 
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Peptide 13 is the reversed version of peptide 6; peptide 14 is a scrambled sequence that contains 
the same amino acid residues as peptide 6 but in a scrambled order; peptide 15 is a random 
sequence that lacks proline; and peptide 16 is a random sequence with proline at the i+2 position. 
(Table 2.2) 
 
Table 2.2. Non-specific control sequences, where sequence 13 and 14 are modifications of peptide 
6, while 15 and 16 are random sequences. 
 
 
2.4.9. IMMUNOSTIMULATORY ACTIVITY OF THE NK92-MI CELLS.  
The ability of the synthetic peptides to activate immune responses from the NK92-MI cells 
was evaluated by the detection of the soluble secreted cytokines, IFN- and TNF-into the culture 
media by a standard ELISA (Figure 2.9.A).(30) In this assay, the NK92-MI cells were incubated 
with either B7H6 (0.5 M) or the peptides 1-6 (10 M) for 24 h. The cells were then harvested 
from culture and the media was examined by ELISA for the secretion of the inflammatory 
cytokines, TNF-(Figure 2.9.B) and IFN- (Figure 2.9.C). Treatment with soluble B7H6 
stimulated secretion of IFN- (260 pg/mL) and TNF- (500 pg/mL) at 0.5 M. Interestingly, 
peptides 1-6 (10 M) activated the secretion of TNF- at noticeable levels (50-180 pg/mL) relative 
to the untreated NK91-MI cells, albeit with about a 3-fold decrease in intensity vs. the native B7H6 
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ligand. Of the most promising candidates in the peptide series, peptide 5, activated secretion of 
TNF- at a concentration of 140 pg/mL and peptide 6 showed the highest levels of TNF- 
production at 180 pg/mL. In this assay, none of the peptides stimulated any observable secretion 
of the inflammatory cytokine, IFN The ability of peptide 6 to stimulate TNF- secretion on 
NK92-MI cells was further compared with four control peptides, 13-16 (Figure 2.9.D). The assay 
revealed that none of the control sequences (10 M) stimulated TNF- secretion after 24 hour 
treatment, even though peptides 13 and 14 are directly related to peptide 6. Furthermore, peptide 
6 maintained notable TNF- stimulating capabilities of the NK cells which was observed at a 2.5-
fold increase relative to the non-specific control peptides (Figure 2.9.D).  
 
Figure 2.9. Immunostimulatory activities of B7H6 and the peptides, 1-6, on the NK92-MI cells. 
(A) Figurative representation of the release of the inflammatory cytokines, TNF- and IFN-, from 
the NK cells upon treatment with B7H6 and peptides, 1-6. ELISA for (B) TNF- and (C) IFN- 
detection following treatment of B7H6 (0.M) and peptides, 1-6, (10 M) on the NK92-MI cells. 
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Production of TNF- by NK cells cultured with the peptides was significantly higher than the 
recorded levels of the control, untreated cells (*p< 0.05; **p< 0.01). There was no significant 
difference for IFN- production. This data is the average of three independent experiments. (D) 
Immunostimulatory activities of the non-specific control peptides 13-16, and the lead peptide 6 on 
the NK92-MI cells (*p< 0.1). This data is the average of three independent experiments. 
 
2.4.10. NK CELLS’ VIABILITY. 
In order to test whether the synthetic peptides, 1-6, were non-toxic to the NK cells, or 
whether the stimulation of TNF- resulted in NK cell-dependent cytoxicity, a Guava Nexin® 
Reagent (EMD Millipore) was used to assess early and late-stage apoptosis by flow cytometry.(31)  
In this assay, the NK92-MI cells were incubated for 24 hours with either B7H6 (0.5 M) or the 
peptides, 1-6, (10 M). After incubation, the cells were centrifuged, washed and stained with the 
Guava Nexin® Reagent for NK cells’ viability analyses using flow cytometry. The results revealed 
no early or late stage apoptotic events for the NK cells treated with soluble B7H6-Fc or the 
synthetic peptides, (Figure 2.10). In all cases, ≥95% non-apoptotic NK cells were detected 
following treatment.   
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Figure 2.10. NK cells’ viability assessed by the Guava Nexin Reagent (EMD Millipore) using 
flow cytometry. The NK92-MI cells were incubated with B7H6 (0.25 M) or the synthetic 
peptides, 1-6, (10 M) for 24 h. The cells were washed with fluorescence-activated cell sorting 
(FACS) buffer and stained with the Guava Nexin Reagent. Flow cytometry analyses of the early 
(lower right), late (upper right), early and late (upper left) stages of apoptosis and the non-apoptotic 
(lower left) cells. Data representative of three independently conducted experiments. 
 
2.5. DISCUSSION 
Biological molecules that can trigger immune responses towards invading pathogens, 
allergens, and cancer have led to the advancement of immunotherapy.(32) Tumor immunotherapy 
involves the activation of white blood cells; either by stimulating lymphocytes ex vivo, followed 
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by re-infusion of the activated cells into the patient. Circulating tumor associated ligands can also 
stimulate  inflammatory responses towards the destruction of the invasive tumor or blockage of 
pro-survival signals.(33-36) In an effort to promote in vivo stimulation of lymphocytes, treatment 
methods implicating cancer vaccines, tumor-associated antigen derived small peptides (TAA-SP) 
or recombinant virus-like particles (VLP), cytokine therapy, and monoclonal antibodies (mAbs) 
have been developed and successfully administered in tumor immunotherapy applications.(32,37,38)  
Among these promising treatment regimes, the peptide-based TAA-SPs potentially encompass an 
underexplored yet promising class of immunostimulatory ligands that may have significant utility 
in clinical oncology. Representatively, the TAA-SP derived from the heat shock chaperone protein 
of 70 kilodalton (Hsp70) has been found to activate and expand NK cells towards potent tumor-
targeted immunotherapy responses.(39,40) In this study, the TAA-SPs derived from B7H6 are 
explored as a potential new class of ligands for eliciting NK cells’ immunostimulatory activities.  
The rational design of the synthetic peptides was based on the co-crystal structure of B7H6 
bound to its receptor NKp30.(20) The peptide sequences were based on the amino acid residues 
selected from segments 82-83 (FG), 59-62 (TSMG) and 125-130 of the FG loop region (VTPLK) 
which constituted peptides 1-3, respectively (Table 2.1). These selected peptides were based on 
the primary sequence of the binding site residues of B7H6 at the active site of the NKp30 
receptor.(20) The binding site residues within the FG loop of B7H6, VTPLK, were found to play a 
key role in B7H6 binding and activation of the NKp30 receptor. Structure analyses revealed that 
a turn-type geometry contributed to binding affinity, which was stabilized by the Pro-Leu residues 
at the i+2 and i+3 positions and the Van der Waals contacts that were made predominantly within 
the hydrophobic NKp30 binding pocket.(20) Thus, the modified sequence 6, TVPLN, was rationally 
designed to study the effect of hydrogen bonding and turn conformation on peptide binding and 
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activity. In this case, the rationale for the exchange of the N-terminal Thr and Val, and replacement 
of the C-terminal Lys for Asn was based on the short peptide sequences which promoted turn 
conformations due to stable hydrogen-bonding interactions with terminal Thr and Asn 
residues.(41,42) Moreover, molecular docking studies revealed four H-bonding interactions in 
between peptide 6 and the NKp30 binding site residues, Gly51 and Val53 (Figure 2.1). The Gly51 
and Val53 residues of NKp30 also contributed in H-bonding of the FG loop residues 125-130 
(VTPLK) of B7-H6, found at the B7H6:NKp30 binding interface.(20) The lengthier peptides (Table 
2.1, sequences 4, 5) were based on the residues (59-62, 82-83, 125-130) of the full length B7H6 
primary sequence that contributed to NKp30 binding, (FGTSMGVTPLK peptide 4), and on the 
residues (82-83, 59-62, 125-130) that contributed to the B7H6 secondary structure which bound 
to the NKp30 receptor (TSMGFGVTPLK, peptide 5). These full-length sequences (Table 2.1, 
sequences 4 and 5) were selected to contain the binding site residues and structural elements that 
effected B7H6 binding and activation of the NKp30 receptor.(20)        
For peptide synthesis, the hydrophilic poly(ethylene glycol) resin (NovaPEG, 0.52 
mmol/g) was chosen because of its known advantages over the hydrophobic polystyrene (PS)-
based resins.(26,29) The hydrophilicity and higher swelling capabilities of the NovaPEG resin in 
H2O, DMF, DCM and TFA, led to improved coupling efficiencies, isolated peptide purities and 
yields of lengthy non-polar sequences that tend to aggregate during the course of SPPS.(26,29) For 
peptide coupling, HCTU was selected as activator, with NMM as base, due to its high coupling 
efficiencies at short coupling times and at lower costs when compared with HATU.(27) The Fmoc-
based SPPS of the peptide sequences (Table 2.1, peptides 1-12) was developed according to 
standard procedures.(26,27,29) Following peptide synthesis, the peptides were coupled with an Ahx 
linker at the N-terminus and selected peptides (Table 2.1, peptides 7-12) were functionalized with 
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FITC for biological studies. Peptides were then cleaved and deprotected with trifluoroacetic acid 
(TFA), using water and triethylsilane (TES) as scavengers for any reactive components. The 
efficiency of the peptide synthesis was determined by RP HPLC and related to the crude purity 
analyses (13-95%) which resulted in sufficient isolated yields (10-44%) for structure-activity 
relationship studies. Furthermore, the integrity of the peptides was confirmed by preparative RP 
HPLC which resulted in peptides of purity>93%. Sequence identities were also validated by ESI 
MS, which confirmed the molecular weights of the peptides as selected mass:charge ratios (Table 
2.1).  
With pure peptides in hand, circular dichroism (CD) spectroscopy was used to evaluate 
their structures in solution.(28,29) Peptides (Table 2.1, sequence 3-6) were dissolved in deionized 
H2O, PBS and a mixture of TFE:H2O (50:50, v/v) in order to assess the influence of solvent on 
peptide structure. In this study, the solvent was found to play a pivotal role on the structures 
adopted by the peptide sequences, as seen by the transitions in conformations from random coil 
(H2O), to alpha-helix (PBS) and turn-type structures (TFE:H2O) (Figure 2.3). All peptides adopted 
similar conformations within the same solvent system, possibly because of their similarities in 
sequences, which included the putative turn-inducing motif, VTPLK, in peptides 3-5, which was 
expected to be stabilized in the modified TVPLN sequence, 6. These peptides were found to adopt 
turn conformations in the TFE:H2O mixture that is known to mimic amphiphilic biological 
environments (i.e. membrane receptors) and stabilize the structure for the most favored peptide 
conformation by promoting intramolecular hydrogen bonding.(43)  This was shown to be based on 
the ability for TFE to aggregate around the peptide, while displacing water, and favoring the 
formation of the intra-peptide hydrogen bonds responsible for the peptide secondary structures. In 
this model TFE:H2O serve to mimic the amphiphilic lipid bilayer microenvironments or those 
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found in membrane spanning proteins.(44,45) Interestingly, the bioactive FG loop region of B7H6 
containing the VTPLK sequence was also found to favor a turn-type conformation when bound to 
the active site of the NKp30 receptor.(20) Thus, this peptide secondary structure motif may be 
contributive towards binding and activity of the B7H6-derived peptides synthesized in this study.    
The NKp30 receptor has been found to be constitutively expressed on all activated and 
resting NK cells.(19)  Flow cytometry was used to ascertain the cell surface expression of NKp30 
on resting NK92-MI cells. High cell surface expression levels (95%) of NKp30 on the NK92-MI 
cells was confirmed by incubating the cells with the APC-labeled anti-NKp30 mAb. 
Comparatively, the soluble form of the Alexa Fluor 488-labeled natural NKp30 ligand, B7H6-Fc, 
also demonstrated high binding affinity (86%, 1 M) for the NK92-MI cells regardless of the 
amount of sample used (20 l vs. 50 l) (Figure 2.5). This is in agreement with the SPR 
experiments, which revealed an equilibrium dissociation constant value in between B7H6 and 
NKp30 of 1.0 ± 0.2 x10-6 M.(21) The binding occupancy of the peptides on the NK92-MI cells were 
then determined in a concentration dependent manner (0.1 - 10 M). All FITC-labeled peptides, 
7-12, were able to bind to the NK92-MI cells with comparable occupancy (80-97%) at 10 M 
relative to the anti-NKp30 mAb (95%) and B7H6 (86%), albeit at a 10-fold higher concentration 
relative to the native B7H6 ligand. Moreover, binding of the peptides to the NK92-MI cells was 
found to be dose-dependent, with strong (80-97%, 10 M), moderate (24-50%, 1 M) and weak 
(3-4%, 0.1 M) binding detected by flow cytometry (Figure 2.4). Thus, all peptides were able to 
bind to the NK92-MI cells with strong occupancy (80-97%) at 10 M.  
Competitive binding experiments were next conducted in order to determine whether the 
peptides bound to the NKp30 receptor on the surface of the NK cells. The NK92-MI cells were 
initially incubated with either Alexa Fluor 488-labeled B7H6 (1 M) or the FITC-labeled peptides, 
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7-12 (10 M) for 30 minutes, followed by treatment with the APC-labeled anti-NKp30 mAb. In 
this assay, the anti-NKp30 mAb was found to partially displace B7H6 (69%) and the peptides (6-
35%) suggesting NKp30 binding specificities for these ligands (Figure 2.6). The partial 
displacement of the peptides and B7H6 may be attributed to the proximal NKp30 binding site 
differences in between the anti-NKp30 mAb (NKp30 residues 91-107 for anti-NKp30 mAb clone 
210845) and B7H6 or the peptide ligands (NKp30 residues 82-83, 59-62, 125-130 for B7H6 and 
peptides).(20,46) Taken altogether, these observations suggests adjacent (allosteric) binding of the 
anti-NKp30 mAb and the NKp30 ligands, B7H6 and the peptides, 7-12, accommodating proximal 
binding site interactions with the NKp30 receptor.  In order to evaluate this hypothesis, a 
complementary competitive binding assay was developed, in which the NK92-MI cells were 
initially incubated with the APC-labeled anti-NKp30 mAb, followed by treatment with either the 
Alexa Fluor 488-labeled B7H6 (1 M) or the FITC-labeled peptides, 7-12 (10 M). In this study, 
no blocking or displacement of the anti-NKp30 mAb was observed after treatment with the ligands 
B7H6 or the peptides (Figure 2.7).These results lend further evidence of the putative allosteric 
binding of the anti-NKp30 mAb and the ligands (B7H6, peptides 7-12) with the target NKp30 
receptor on the surface of the NK92-MI cells. To further asses the binding specificities of the B7H6 
derived peptides, a competitive binding study in which NK92-MI cells were incubated first with 
unlabeled B7H6 (1 M) for 30 min, following incubation with FITC-labeled peptides (7-12), 
(Figure 2.8). Flow cytometry results revealed consistent binding of the peptidic ligands, even after 
B7H6 treatment, suggesting strong binding occupancy of the peptidic ligands on the NK92-MI 
cells.  
Following the binding studies, the immunostimulatory activities of B7H6 and the peptides, 
1-6, on the NK92-MI cells were next evaluated by the release of the inflammatory cytokines, TNF-
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 and IFN-. In this assay, the NK92-MI cells were incubated with either B7H6 (0.5 M) or the 
peptides 1-6 (10 M) for 24 hours followed by the recovery of the supernatant which was analyzed 
for the release of TNF- and IFN- by ELISA. The soluble B7H6 was capable of activating the 
secretion of TNF- (>500 pg/mL), whereas, peptides 1-4 scarcely activated secretion (<100 
pg/mL), and peptides 5 and 6 showed notable production of this cytokine (140 pg/mL and 180 
pg/mL, respectively) from the NK cells (Figure 2.9.B). Interestingly, peptide 6, which was 
designed to stabilize the putative turn geometry responsible for NK cells’ binding and activation 
showed the highest TNF- secretion. This bio-active turn conformation was confirmed by the CD 
studies in TFE:H2O (Figure 2.3.C) and suggests a potential link in between peptide turn geometry 
and the NK cells’ immunostimualtory activity observed for this lead peptide sequence. Moreover, 
B7H6 was found to activate secretion of IFN- (>260 pg/mL) whereas the peptides had little (<100 
pg/mL) effect on the stimulation of this inflammatory cytokine (Figure 2.9.C). Further 
mechanistic studies will be conducted in order to elucidate the observed selectivity of the secreted 
cytokines from the NK cells. Four control, non-specific peptides, 13-16, based on reverse, 
scrambled and random sequences were evaluated for their ability to stimulate TNF- secretion 
from the NK92-MI cells. None of the control peptides 13-16 were capable of activating cytokine 
release despite peptides 13 and 14 being directly related to peptide 6 (Figure 2.9.D) 
Comparatively, peptide 6 triggered a notable 2.5-fold increase in TNF- secretion from the NK 
cells when directly compared to the control, non-specific peptides.  
In a final experiment, the toxicity of the peptides, 1-6, was analyzed by probing for the 
characteristic markers of early (externalization of phosphatidylserine, PS) and late-stage (loss of 
membrane integrity) apoptosis.(47) Apoptosis was evaluated by flow cytometry using the Guava 
Nexin Reagent ®.(31) This reagent utilizes Annexin V as a marker of early apoptotic events due to 
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its high affinity for PS, and 7- aminoactinomycin D (7-AAD), a cell permeable dye in the event of 
compromised cell membranes which occur during late-stage apoptosis. In this assay, the NK92-
MI cells were incubated (24 h) with B7H6 (0.5 M) or peptides 1-6 (10 M) and then analyzed 
by flow cytometry using the Guava Nexin Reagent®. In all treatment cases, flow cytometry 
revealed viable NK cells, with little (<5%) observable cells in early, late or both stages of apoptosis 
(Figure 2.10). Thus, B7H6 (0.5 M) and the peptides 1-6, (10 M) were found to be well tolerated 
within the NK92-MI cells at concentration levels which were used for the binding and 
immunostimulatory studies.  
 
2.6. CONCLUSIONS 
In this study, the design, synthesis, and characterization of a novel class of NK cell-
dependent immunostimulatory peptides (IPs), derived from the binding interface of B7H6 and 
NKp30 have been discovered. A structure–activity relationship study revealed that the synthetic 
peptides, 3-6, exhibited secondary structures that varied on the solvent system. They also displayed 
the putative turn conformation in a TFE:H2O mixture that was expected to contribute to NKp30 
receptor binding and the NK cells’ immunostimulatory activities. Flow cytometry analyses 
confirmed binding of the FITC-labeled peptides, 7-12, to the NK cells at 10 M concentrations, 
and partial displacement upon treatment with the anti-NKp30 mAb suggests NKp30 binding 
specificities. Moreover, ELISA demonstrated that peptides 5 and 6 notably stimulated the secretion 
of TNF- but not IFN-while exhibiting no observable cytotoxicity (apoptosis) to the NK92-MI 
cells. Taken altogether, these studies have effectively paved the way for the analyses of this new 
class of B7H6-derived TAA-SP in tumor immunotherapy applications. The latter is a current focus 
of our on-going research program in anti-cancer drug design and development.  
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2.7. MATERIALS AND METHODS 
2.7.1 MATERIALS 
Aminoacids for the synthesis of all peptides, Fmoc-Lys(Boc), Fmoc-Leu, Fmoc-Pro, 
Fmoc-Thr(tBu), Fmoc-Val, Fmoc-Gly, Fmoc-Phe, Fmoc-Met, Fmoc-Ser(tBu), Fmoc-Thr(tBu), 
and Fmoc-Ahx, were purchased from Novabiochem (San Diego, CA, USA). Peptide syntheses 
were conducted on a Rink Amide ChemMatrix (0.52 mmol/g) (Biotage Inc., Charlotte NC, USA). 
2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate, HCTU, 
was purchased from Advanced ChemTech (Louisville, KY, USA). Fluorescein isothiocyanate, 
FITC, was purchased from ThermoScientific (Rockford, IL, USA) as a mixture of isomers and 
used in the dark to fluorescently label all peptides. Trifluoroacetic acid, TFA, (Biograde) was 
purchased from VWR (Radnor, PA, USA); N-N-dimethylformamide, DMF, acetonitrile, MeCN, 
methyl alcohol, MeOH, and dichloromethane, DCM, were all purchased from MACRON in ACS 
grade (Center Valley, PA, USA). Piperidine was purchased from EMD Millipore (Billerica, MA, 
USA); formic acid (97%), FA, triethylsilane (98+%), TES and pyridine (ACS, 99%) were 
purchased form Alfa Aesar (Ward Hill, MA, USA). N-methylmorpholine (99%), NMM, was 
purchased from Acros Organics (Pittsburg, PA, USA). Diethyl ether (99%, ACS), Et2O, used to 
precipitate peptides was purchased from Sigma Aldrich (St. Louis, MO, USA). All chemicals were 
used directly as received.  
 
2.7.2. PEPTIDE SYNTHESIS 
All peptides were synthesized by stepwise manual solid phase peptide synthesis using 
Fmoc-chemistry. Fmoc-amino acids (300 mol%, 0.45 mmol) were coupled on a Rink amide linker 
poly(ethylene glycol) solid support (0.52 mmol/g, 0.15 mmols) for 1 h using [HCTU (300 mol%, 
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0.45 mmol), NMM (600 mol%, 0.9 mmol) in DMF (4 mL). A 20% piperidine in DMF solution (4 
mL) was used for Fmoc deprotection (30 min). Amino acid couplings and Fmoc deprotections 
were repeated until the desired sequences were completed. Following peptide synthesis, solid 
support bound peptide was separated (100 mg, 0.052 mmol) for FITC-labeling. The resin was 
swollen in DMF for 1 h. A slurry of FITC (1.1 equiv., 0.057 mmol) in pyridine/DMF/DCM (12:7:5 
v/v) was prepared and added to the reaction vessel for overnight reaction on an overhead shaker. 
After FITC-labeling was completed, the resin was washed with DMF (3 x 3 mL), MeOH (3 x 3 
mL), and DCM (3 x 3 mL). Peptide cleavage and deprotection from the solid support was 
accomplished using a mixture of TFA:TES:H2O, (95:2.5:2.5 v/v/v) for 3 h. Peptide samples were 
concentrated under nitrogen to a viscous oil, precipitated with cold Et2O, and centrifuged to a white 
pellet. The supernatant was decanted and the peptide pellets were dissolved in MeOH/H2O for 
LCMS analyses. Sample analyses were performed on an Agilent 1100 series ESI-LCMS with 
single quadrupole mass analyzer and LC conditions which used a linear binary gradient (2-80% 
MeOH/H2O, 0.1% TFA, over 18 min) in positive mode. Analytical RP-HPLC was performed using 
a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m particle size) using a linear binary 
gradient, 2-60% or 2-82% MeCN/H2O, 0.1% TFA, over 18 min at 25°C, with a 1 mL/min flow 
rate and detection at 220 nm. Samples collected after purification were lyophilized to a white solid 
and re-dissolved in 50:50 v/v H2O:MeOH to confirm purity and identity by LCMS analyses. 
 
2.7.3. UV-VIS SPECTROSCOPY 
The concentrations of the peptide solutions were determined by UV/Vis spectrophotometry 
at 214 nm ( value of peptides was calculated as described by Kuipers et. al. 214 = 
peptidebond)(npeptidebonds) + Σ (aminoacid(i))(naminoacid(i)).(48) The analyses were conducted on an 8452A 
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Diode Array Spectrophotometer from Hewlett Packard, and concentrations were standardized at 
accordingly for each peptide. 
 
2.7.4. CIRCULAR DICHROISM SPECTROSCOPY 
The secondary structures of the synthetic peptides were determined by CD spectroscopy 
using an Aviv 62AD DS CD spectrophotometer (Lakefield, NJ). For CD analysis, peptides were 
dissolved in deionized water, PBS or a mixture of TFE:H2O, (50:50 v/v), and concentrations were 
standardized at 40 M for each peptide by UV-Vis spectroscopy. The CD spectra for the peptides 
(40 M) were collected in a 1 mL cuvette (1 cm path length). The data was collected using a 1 nm 
bandwidth and 1 min step size for wavelengths from 190 to 280 nm at 25°C. The raw data obtained 
was then converted to molar ellipticity ([Ɵ] = Ɵ/cl, where Ɵ is the relative ellipticity (mdeg), c is 
the peptide concentration (M), and l is the path length (mm)), was blank corrected, and plotted as 
a function of molar ellipticity [Ɵ] versus wavelength (nm). 
 
2.7.5. CELL LINES AND CELL CULTURE 
The human NK cells, cell line NK92-MI (American Type Culture Collection, ATCC), were 
cultured in MEME, (Sigma Aldrich). The cell culture media was alpha modified with sodium 
bicarbonate and without ribonucleosides and deoxyribonucleosides, purchased from Sigma 
Aldrich. Media was supplemented with 2 mM L-glutamine (Lonza, Walkersville, MD, USA); 0.2 
mM myo-inositol, 0.1 mM 2-mercaptoethanol (99%), and 0.02 mM folic acid (≥97%) (Sigma 
Aldrich) and 1% (v/v) penicillin/streptomycin (Sigma Aldrich). Heat-inactivated fetal bovine 
serum and horse serum (Sigma Aldrich) were added to a final concentration of 12.5% in total 
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volume. Cell cultures were maintained at 2-3x105 viable cells/mL at 37°C in 5% CO2 humidified 
air. 
2.7.6. FLOW CYTOMETRY 
For detection of cell surface expression levels of NKp30, the NK92-MI cells were washed 
with FACS buffer (PBS, 1% FBS), suspended in APC-labeled human NKp30 mAb (2 g/mL in 
FACS, clone 210845 from R&D Systems), and incubated at room temperature for 30 minutes in 
the dark. Cells were then washed and analyzed by flow cytometry on a MACSQuant® analyzer 
(MiltenyilBiotec). 
To determine direct binding of B7H6 and the synthetic peptides, 7-12, NK92-MI cells were 
washed with FACS buffer and suspended with either soluble B7H6 (1 M in PBS) labeled with 
AlexaFluor 488 Microscale Protein labeling Kit (Life Technologies), or the FITC-labeled peptides 
(0.1 - 10 M in PBS) for 30 min (R.T., dark), washed and analyzed by flow cytometry. 
To determine the optimal amount of B7H6 for direct binding studies, NK92-MI cells were 
washed with FACS buffer and suspended with either soluble B7H6 (20 l, 1 M in PBS) or soluble 
B7H6 (50 l, 1 M in PBS), both labeled with AlexaFluor 488 Microscale Protein labeling Kit 
(Life Technologies), for 30 min (R.T., dark), washed and analyzed by flow cytometry.  
For competitive displacement studies, NK92-MI cells were initially suspended with either 
AlexaFluor 488-labeled soluble B7H6 (1 M in PBS) or the FITC-labeled peptides, 7-12 (10 M 
in PBS) for 30 min (R.T., dark). NK cells were washed with FACS buffer, centrifuged and 
suspended with the APC-labeled human NKp30 mAb (2 g/mL in FACS) for another 30 minutes 
(R.T., dark). Cells were then washed with FACS buffer and analyzed by flow cytometry. 
For competitive blocking studies, NK92-MI cells were initially treated with the APC-
labeled human NKp30 mAb (2 g/mL in FACS) for 30 min (R.T., dark). NK cells were washed 
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with FACS buffer, centrifuged and suspended with either AlexaFluor 488-labeled soluble B7H6 
(1 M in PBS) or the FITC-labeled peptides, 7-12 (10 M in PBS) for an additional 30 min (R.T., 
dark). Cells were finally washed with FACS buffer and analyzed by flow cytometry. 
For peptide blocking studies, NK92-MI cells were initially treated with soluble B7H6 (1 
M in PBS) for 30 min (R.T.). NK cells were washed with FACS buffer, centrifuged and 
suspended with the FITC-labeled peptides, 7-12 (10 M in PBS) for an additional 30 min (R.T., 
dark). Cells were finally washed with FACS buffer and analyzed by flow cytometry. 
 
2.7.7. ENZYME-LINKED IMMUNOSORBENT ASSAY 
To assess the ability of the synthesized peptides to elicit immunostimulatory activity; the 
NK92-MI cells were incubated in 96 well plates at 5x104 viable cells/well, and left untreated with  
growing media, or treated with B7H6 (0.5 M) or the peptides, 1-6 and 13-16 (10 M) at 37°C in 
5% CO2 humidified air. The cell culture was incubated for 24 h. and the supernatants were 
recovered for the detection of the inflammatory cytokines IFN- or TNF- by ELISA kits 
following vendor instructions (ThermoScientific Inc.). 
 
2.7.8. STATISTICAL ANALYSIS 
Cytokine data were analyzed by using the unpaired two-tailed t test. GraphPad Prism 4 
provided the software for the statistical analysis. 
 
2.7.9. CELL VIABILITY 
To evaluate the NK cells’ viability following treatment with the synthetic peptides, 1-6, or 
B7H6, the NK92-MI cells were incubated for 24 h in a 96 well plate, at 5x104 viable cells/well. 
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NK cells were left untreated, and treated with soluble B7H6 (0.5 M) or the peptides, 1-6 (10 M) 
at 37°C in 5% CO2 humidified air. Cells were then collected and washed with FACS buffer, 
centrifuged, and suspended in Guava Nexin Reagent® (100 L/tube, from EMD Millipore). 
Following incubation (20 min) at room temperature in the dark, the NK cells were analyzed for 
early and late apoptotic events by flow cytometry following the vendor instructions.  
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CHAPTER 3: PEP42, A CANCER-TARGETING PEPTIDE THAT RECOGNIZES CELL 
SURFACE GRP78 ON THE SURFACE OF CANCER CELLS 
3.1. ABSTRACT 
The need for selective cancer targeting ligands, that can selectively and efficiently target 
cancer cells, has led to more efficient delivery of drug payloads while reducing harmful side 
effects. In an effort to identify novel therapeutic leads, a series of cyclic peptides generated by 
phage-display bio-panning led to the isolation of peptidic ligands which targeted and penetrated 
human melanoma Me6652/4 tumor cells. The peptidic ligand was identified as a 13-mer cyclic 
peptide, namely Pep42, which selectively binds and internalizes into Me6652/4 cells. Interestingly, 
Pep42 was found to bind selectively to the oncoprotein receptor, GRP78, a chaperone protein and 
key modulator of the UPR mechanism. GRP78 is also known to be overexpressed and cell surface 
localized in tumor cells. In this study, Pep42, its FITC-labeled derivatives and a series of 
poly(ethylene glycol)-linked Pep42 sequences with reactive N-succinimidyl carbamate linkages 
have been developed by solid phase peptide synthesis. Pep42 and its FITC-labeled derivatives 
have been tested for their capabilities to bind to the HepG2 human hepatocellular carcinoma cells. 
Flow cytometry revealed comparable binding of the synthetic peptides relative to the anti-GRP78 
primary antibody at equal concentrations (100 nM). A blocking assay in between the human anti-
NKp30 mAb or Pep42, and the specific N-20 GRP78 peptide blocker showed similar blocking 
capabilities of either the primary antibody or Pep42, suggesting binding specificity to GRP78.  In 
a cell death assay, Pep42 was found to be non-toxic. Moreover, the reactive N-succinimidyl 
carbamate derived peptides were envisioned to behave as reactive probes for their incorporation 
within bioactive proteins such as B7H6. Therefore, Pep42 may prove to be a promising cancer 
targeting peptide for the development of immunostimulatory peptide-protein conjugates. 
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3.2. INTRODUCTION 
The unfolded protein response (UPR) is an adaptive mechanism responsible for 
maintaining the endoplasmic reticulum (ER) homeostasis.(1) The ER a cellular organelle primarily 
responsible for protein synthesis, folding and maturation. The 78 kilodalton glucose regulated 
protein 78, GRP78, (also known as the immunoglobulin heavy chain binding protein BiP), is a 
chaperone and a member of the heat shock family of proteins, that plays a key role in protein 
folding and regulation of the UPR mechanism in the ER.(2) Moreover, GRP78  regulates 
intracellular signaling pathways associated with development of the embryo, aging, Ca2+ 
homeostasis, and the insulin/IGF-1 signaling pathway.(3) When in homeostatic conditions of the 
ER, GRP78 binds to the three transmembrane sensors of ER stress. These include the activating 
transcription factor 6 (ATF6)  and  isoforms, the protein kinase RNA-like ER kinase (PERK), 
and the inositol-requiring enzyme 1 (IRE1), and IRE1thus inhibiting its activity.(4) Under 
stress conditions of the ER, GRP78 is released from the transmembrane stress sensors leading to 
its activation and initiation of the UPR mechanism. The UPR mechanism results in reduced protein 
translation, degradation of misfolded proteins, an increased protein folding capacity and increased 
efficiency of quality control mechanisms associated with the ER; including the upregulation of 
GRP78.(1,5)  Under chronic ER stress conditions, the UPR is capable of triggering cell death by 
apoptosis.(6,7) 
The cancer microenvironment is characterized by conditions such as altered glucose 
metabolism, altered blood flow, and hypoxia; all conditions that induce ER stress.(8) Under these 
conditions, ER stress signaling pathways play an important role in tumor progression and survival 
(8) Tumor transformation promotes GRP78 overexpression and cell surface translocation, where 
GRP78 plays a pivotal role as an oncoprotein receptor modulating cell proliferation, conferring 
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apoptosis resistance and chemoresistance. Thus, GRP78 maintains inherent pro-survival 
characteristics that aid in tumor progression and metastatic spread (Figure 3.1).(9-13) Moreover, 
GRP78 has been found to be cell surface expressed and localized on cancer cells, but not on normal 
tissues, making it a valuable biomarker for the development of cancer-targeting strategies.(13-16) 
Finally, cell surface expression of GRP78 has enabled selective tumor targeting, as demonstrated 
by the use of antibodies and short peptidic ligands, potentially minimizing off-tumor side effects 
and increasing delivery efficiency.(17-19) 
 
Figure 3.1. Role of GRP78 under physiological and pathological stress. Figure adapted 
from Curr Opin Cell Biol, 2011, 23, 150-156.3 
 
In an effort to identify peptidic ligands for drug delivery that could target cell surface 
GRP78 on cancer cells with high specificity, Janda and co-workers reported the phage display bio-
panning peptide library selection of Pep42.(14) Importantly, Pep42, a 13-mer cyclic peptide of 
amino acid sequence CTVALPGGYVRVC, bound selectively to the highly metastatic human 
melanoma cell line Me6652/4, but poorly to the low metastatic cell line Me6652/56 that exhibits 
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normal GRP78 function and expression.(14,20) Interestingly, internalization of a mutated Pep42 
cyclic sequence, Mut42, in which the C-terminal Val12 was substituted for Lys, for fluorescein 
isothiocyanate (FITC) labeling, revealed that the cyclic constraint was required for cell uptake and 
internalization. Alternatively, the linear sequence, Lin42, failed to internalize within cells (Figure 
3.2).(14) Moreover, a photoaffinity assay of the photoliable peptide ligand Mut42-Bpa-biotin, 
followed by SDS-PAGE and western blot analyses, identified GRP78 as the cell surface receptor 
for Pep42.(14) Finally, pre-incubation of the Me6652/4 cell line with anti-GRP78 monoclonal 
antibody inhibited binding and subsequent internalization of Mut42. Taken together, these results 
demonstrates that Pep42 selectively binds to cell surface GRP78 and internalizes through receptor 
mediated endocytosis.(14)  
 
 
 
 
Figure 3.2. Role of Pep42 structure on Me6652/4 cell internalization. Figure adapted 
from Biochemistry, 2006, 45, 9434-9444.14 
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In a more recent study, Joseph and co-workers, evaluated the internalization capabilities of 
Pep42 when coupled to varying lengths (3-12) of poly(arginine) sequences, known to possess ionic 
binding and cell membrane translocation capabilities.(21-23)  Flow cytometry studies on the cell 
surface GRP78 overexpressing cell line HepG2 revealed comparable binding affinity and 
selectivity of the FITC-labeled Pep42 sequence compared to the Alexa Fluor 488-labeled N-20 
anti-GRP78 primary antibody.(24) Interestingly, the FITC-labeled Pep42-(poly)arginine peptides 
showed increased fluorescence signaling activity that was dependent on the length of the 
poly(arginine) sequences (0, 3, 6, 9, 12). These results indicate the cell translocation capabilities 
of Pep42 is contingent on the lengths of the polyarginine sequences, with the lengthier 
polyarginines (6-12) providing greater cell uptake when compared to the shorter polyarginine 
sequences (0-3). Moreover, FITC signaling  decreased when the HepG2 cells were pre-incubated 
with the N-20 GRP78 specific peptide blocker then followed by peptide treatment, suggesting 
antibody blocking of GRP78 and inhibition of GRP78-dependent uptake of the FITC-labeled 
poly(arginine) derived Pep42 sequences (Figure 3.3).(24) Laser scanning confocal microscopy 
studies confirmed the selective binding and internalization of the FITC-Pep42-(poly)arginine 
sequences within HepG2 cells, which was also blocked when the cells were pretreated with the N-
20 GRP78 peptide blocker.(24) 
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Figure 3.3. Fluorescence signaling activity of FITC-Pep42-(poly)arginine sequences on 
human hepatocellular carcinoma cell line HepG2. Figure adapted from J. Pept. Sci., 2014, 20, 
736-745.24 
 
Highlighting the previous work conducted by Joseph and co-workers, in this chapter we 
report the synthesis, characterization and biological evaluation of Pep42, and its FITC-labeled 
derivative, on the human hepatocellular carcinoma cell line HepG2. Moreover, we also report the 
activation of Pep42 with a reactive N-succinimidyl carbamate linkage, which was envisioned to 
facilitate conjugation with bio-active proteins, including B7H6. These studies will set the stage for 
the development of GRP78-targeting immunostimultaory peptide-protein conjugates (Chapter 4). 
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3.3. PROJECT OBJECTIVES 
The main research objectives of this chapter are related to the synthesis, characterization, 
and biological evaluation of Pep42 and its FITC-labeled sequences. Moreover, a description 
detailing the synthesis and characterization of poly(ethylene glycol) PEG-derived Pep42 is also 
reported in this chapter. The incorporation of a C-terminal Lys is used for activation via N-
succinimidyl carbamate (NSC) chemistry. The latter is expected to be useful for the site-selective 
conjugation of Pep42 with bio-active proteins, such as B7H6, for the development of peptide-
protein conjugates that may be applied in cancer immunotherapy applications. The peptides were 
developed by the Fmoc SPPS method for the rapid production of the Pep42 derived sequences. 
The incorporation of FITC was used for labeling Pep42 for biological studies in HepG2 cells, 
whereas PEG-linked Pep42 with the C-terminal NSCs were synthesized for follow-up 
bioconjugation studies. Following peptide synthesis, ESI-LCMS was used to analyze, purify and 
confirm the identities of the peptides. The binding affinity, specificity, and internalization 
capabilities of the FITC derived Pep42 were determined in HepG2 cells which were found to 
overexpress GRP78 at the cell surface according to flow cytometry. Therefore, Pep42 exhibits the 
effective capabilities to target HepG2 cells that display cell surface GRP78. These findings are 
important for the development of cell surface recognition studies that can lead to the identification 
of targeting and activating ligands for tumor immunotherapy applications (Chapter 4). Moreover, 
the toxicity of these synthetic peptides to HepG2 cells was assessed by evaluating apoptosis using 
a Trypan blue cell exclusion staining technique. Pep42 was found to be non-toxic to the HepG2 
cells, underscoring its potential benign utility as a targeting or delivery vector in tumors cells that 
express cell surface GRP78.   
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3.4. RESULTS 
3.4.1. SOLID PHASE PEPTIDE SYNTHESIS 
The synthesis of the Pep42 peptide sequence CTVALPGGYVRVC-CONH2, 17, was 
accomplished by conventional Fmoc-based solid phase peptide synthesis on a Rink amide linker 
hydrophilic PEG-based resin (NovaPEG, 0.52mmol/g).(24) In our synthetic approach, HCTU was 
selected as coupling reagent with NMM acting as base and DMF as solvent resulting good coupling 
efficiencies in 20 min.(26) Fmoc deblocking was accomplished with piperidine and the N-terminus 
was elongated with 6-aminohexanoic acid, (Ahx) resulting in the Ahx-Pep42 sequence which was 
further labeled with FITC to yield peptide 2 for its use in biological studies (Figure 3.4). Peptides, 
17 and 18, were further purified by semi-preparative RP HPLC and isolated in purities ≥93%, and 
pure yields of 14% and 24% respectively. The identities of the synthetic peptides 17 and 18 were 
confirmed by mass spectrometry which validated sequence composition based on mass/charge 
ratios (Table 3.1). 
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Figure 3.4. Representative solid phase peptide synthesis and LCMS characterization for peptides 
17 and 18. (A) Fmoc-solid-phase peptide synthesis and FITC labeling for peptides 17 and 18, 
respectively. (B) RP-HPLC for CTVALPGGYVRVC-CONH2, 17 and (C) MS for 
CTVALPGGYVRVC-CONH2, 17. 
 
Table 3.1. Characterization of the synthetic peptides 17 and 18. 
 
 
The synthesis of the C-terminal PEG-based Pep42 sequences were also accomplished by 
conventional Fmoc-based solid phase peptide synthesis on the NovaPEG resin (0.47mmol/g).(24,26) 
Peptides 19-21 were further labeled with FITC to obtain peptides 22-24 for their use in biological 
studies (Figure 3.5). Peptides were recovered in crude yields (16-41%) and purities (35-82%) 
according to RP HPLC. The identities of the synthetic peptides were confirmed by mass 
spectrometry which validated sequence composition based on mass/charge ratios (Table 3.2).  
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Figure 3.5. Representative solid phase peptide synthesis and LCMS characterization for peptides 
19 and 22. (A) Fmoc-solid-phase peptide synthesis and FITC labeling for peptides 19 and 22, 
respectively. (B) RP HPLC analyses for FITC-Ahx-CTVALPGGYVRVC-PEG3-K-CONH2, 22 
and (C) ESI-MS analyses for FITC-Ahx-CTVALPGGYVRVC-PEG3-K-CONH2, 22. 
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Table 3.2. Characterization of the synthetic peptides 19-24.
 
 
3.4.2 SOLUTION-PHASE SYNTHESIS OF THE NSC DERIVED PEPTIDES  
The crude FITC labeled synthetic peptides, 22-24, were further activated at the -amino 
group of the C-terminal Lys residue using described NSC chemistry for activating and ligating 
peptides onto proteins.(32) In our synthetic approach, crude peptides 22-24 were reacted with excess 
disuccinimidyl carbonate (DSC) and trimethylamine (TEA) in anhydrous DMF for 1 h at room 
temperature. Under these reaction conditions, the formation of the C-terminal NSC-derived 
peptides, 25-27, were closely monitored by LC-MS (Figure 3.6). The analyses confirmed good 
conversions (30-75%) and stability of the NSC-activated peptides as little decomposition was 
observed following work-up and purification of the peptides. The characterization data for the 
peptides indicated good crude yield recoveries (13-28%) and purities (24-31%) followed by RP 
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HPLC purifications. Moreover, the identities of the peptides, 25-27, were confirmed as their 
mass:charge ratios using ESI MS (Table 3.3).  
 
Figure 3.6. Schematic representation of the formation of the NSC peptides 25-27 and LCMS 
characterization of peptide 25. (A) General schematic of the DSC reaction with the FITC-labeled 
Pep42 derived peptides. (B) RP-HPLC analyses of FITC-Ahx-CTVALPGGYVRVC-PEG3-
K(NSC)-CONH2, 25. (C) ESI-MS analyses of FITC-Ahx-CTVALPGGYVRVC-PEG3-K(NSC)-
CONH2, 25. 
 
Table 3.3. Characterization of the NSC derived peptides 25-27. 
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3.4.3. DIRECT BINDING STUDIES OF FITC-Pep42 ON THE HepG2 CELLS. 
In order to evaluate the ability of the FITC-labeled Pep42, 18, to bind to the cell surface of 
human hepatocellular carcinoma cells, HepG2 cells were incubated for 30 minutes with either 
AlexaFluor 488-labeled N-20 anti-GRP78  mAb  (100 nM) or peptide 18 (100 nM) in PBS. Their 
binding capabilities were compared by flow cytometry (Figure 3.7). Flow cytometry revealed 
comparable HepG2 cell binding (5.71-6.53%) between the anti-GRP78 mAb and the FITC-Pep42 
peptide, 18. Moreover, the peptide was found to display selective binding on the HepG2 cells, as 
seen with a decreased signal (3.12%) when HepG2 cells were pre-incubated with the 
corresponding N-20 GRP78 peptide blocker (10 mg/ml) (Figure 3.7). 
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Figure 3.7. Binding studies on the HepG2 cells. (A) Figurative representation of the HepG2 cells’ 
binding to either the AlexaFluor 488-labeled N-20 anti-GRP78 mAb or the FITC-labeled peptide 
18. (B) Figurative representation of the HepG2 cells’ pretreated with N-20 GRP78 peptide blocker 
followed by treatment with either the AlexaFluor 488-labeled N-20 anti-GRP78 mAb or the FITC-
labeled peptide 18. (C) Flow cytometry analyses of the HepG2 cells’ binding to the AlexaFluor 
488-labeled N-20 anti-GRP78 mAb (100 nM) or the FITC-labeled peptide 18 (100 nM), with or 
without N-20 GRP78 peptide blocker (10 mg/ml).  
79 
 
3.4.4. HEPG2 CELLS’ VIABILITY. 
In order to test the cytotoxicity of the synthetic Pep42, a Trypan blue cell staining assay 
was conducted with the HepG2 cells treated with Pep42. Cell viability assays quantified the 
number of dead cells, 5-10%, following peptide treatment at a concentration of 0.15 mM (Figure 
3.8). Therefore, Pep42 was found to be non-toxic to the HepG2 cells, underscoring its potential 
utility as a safe, tumor targeting delivery vector.  
 
Figure 3.8. HepG2 cells’ viability assessed by Trypan blue staining assay. The HepG2 cells were 
incubated with either no treatment (control) or the synthetic peptide, 17, (0.15m) for 48 h at 37 
°C. The cells were then treated with enzyme-free dissociation buffer for 3 min at 37 °C, re-
suspended in PBS, and stained with Trypan blue 0.4 % stain (100 l). Cell viability was counted 
using a countess automated cell counter. Statistical significance was determined by analysis of 
variance (p<0.05). 
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3.5. DISCUSSION 
Synthesis of the cyclic hydrophobic peptide Pep42, 17, its FITC-labeled derivative, 18, and 
the PEG-derived sequences, 19-24, were accomplished using the hydrophilic NovaPEG resin. This 
resin was chosen due to its high swelling capabilities in H2O, DMF, DCM and TFA, that results 
in improved coupling efficiencies, better isolated peptide purities and yields during solid phase 
peptide synthesis (SPPS). This resin has been used in the synthesis of challenging, hydrophobic 
peptide sequences and has improved synthesis yields and peptide crude purities by reducing 
peptide aggregation on solid phase. The higher swelling capabilities of the PEG-based resins 
function to enhance the surface area for reaction on solid phase. Therefore, these resins have been 
found to outperform the classical Merrifield-based polystyrene resins and are in regular use in 
Fmoc-based solid phase peptide synthesis.(27) The Fmoc-SPPS protocol followed for peptide 
synthesis has been previously described in Chapter 2, and was developed according to standard 
procedures for the synthesis of Pep42 17, and FITC-labeled Pep42, 18, and the PEG-derived 
sequences, 19-24,  (Figures 3.4 and 3.5).(24,25) The efficiency of the peptide synthesis procedure 
was analyzed by RP-HPLC and revealed sufficient peptide crude purities (93-95%) and isolated 
yields (14-24%) for further biological investigations. Key to the efficient synthesis of Pep42 is the 
quantitative conversion of the linear, free thiol, to the cyclic, disulfide-linked, Pep42 sequence. In 
our method, air oxidation in a combination of H2O:MeOH, resulted in slow but complete 
conversion of linear to cyclic Pep42. Alternatively, air oxidation in the presence of denaturants 
including GnHCl, may be employed to enhance the rate of the disulfide bond forming reaction but 
with the requirement of additional desalting and refolding steps.(28) The Pep42 sequence identities 
were validated by ESI-MS, and confirmed the molecular weights of the peptides as selected 
mass:charge ratios (Table 3.1).  
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Synthesis of the PEG-derived Pep42 sequences, 19-21, and their FITC-labeled derivatives, 
22-24, was also accomplished by standard Fmoc-SPPS on the NovaPEG resin as described above. 
The PEG linkers (3, 6, 12) were found to be amenable to standard Fmoc-SPPS procedures and 
incorporated as their Fmoc-NH-PEG3-propionic acid for the synthesis of peptides 19-21, and the 
FITC-labeled peptides, 22-24 (Figure 3.5).(24,26) Peptide synthesis was analyzed by RP-HPLC and 
revealed good crude purities (35-82%) and yields (16-41%), presumably due to the effect of the 
PEG-linker, which has been shown to reduce aggregation and poor coupling efficiencies of 
lengthy, hydrophobic  sequences during the course of Fmoc-SPPS.(25) Peptide sequence identities 
(19-24) were validated by ESI-MS, that confirmed the molecular weights of the peptides as 
selected mass:charge ratios (Table 3.2). 
The FITC-labeled Pep42 peptides 22-24 were then converted to their active NSC 
derivatives 25-27 following a literature described activation procedure.(32) In our synthetic method, 
the crude peptides 22-24 with reactive C-terminal Lys were activated with an excess of DSC and 
TEA in anhydrous DMF, under N2 conditions, to afford the NSC activated peptides, 25-27 (Figure 
3.6). The -amino group of Lys was expected to be selectively activated by these reaction 
conditions due to its enhanced nucleophilcity in comparison to the remaining residues within the 
sequence. However, side reactions have been reported, due to the generation of reactive 
isocyanates that can be minimized by the addition of substoichiometric amounts of TEA. (32) 
Unstable isocyanates may react with other, potentially nucleophilic groups such as alcohols, thiols 
and phenols that may contribute to lower selectivity and the formation of side-products. Stable 
cyclic urea products may also be anticipated by the addition of multiple Lys residues within the 
peptide sequence. In our case, reaction conditions were adopted to minimize unwanted side 
reactions and to favor the formation of the desired NSC-activated peptides. Following activation, 
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the reaction was quenched with a 1% TFA/H2O. The formation of the NSC-derived peptides, 25-
27, was confirmed by ESI-MS and RP-HPLC. Further RP-HPLC analyses confirmed the 
generation of a more hydrophobic NSC derivative shown by the more retained peaks in two solvent 
systems MeOH/H2O and MeCN/H2O. ESI-MS analyses of the NSC-derived peptides confirmed 
activation at the expected  amino group of the Lys residue in the peptide sequence, and showed a 
stable NSC derivative in solution, even after 48 h of the activation reaction. Further ESI-MS 
analyses were used to calculate the percent conversions, indicating efficient production of the 
NSC-derived peptides using the reported conditions (30-75%) (Table 3.3.). The NSC-derived 
Pep42 sequences may therefore be applied to the ligation with B7H6, for the generation of 
bifunctional peptide-protein conjugates that can target GRP78 presenting tumor cells and effect 
NK-dependent immunostimulatory activity towards their eradication. A brief description of this 
on-going and future work is presented briefly in Chapter 4.   
The HepG2 hepatoblastoma cell line is known to express GRP78 at the cell surface. Previous 
studies have determined that GRP78 knockdown in HepG2 cells results in notable cell death, 
indicating that the HepG2 cells are addicted to GRP78.(29,30) Flow cytometry assays were used to 
confirm the cell surface expression levels of GRP78 on the HepG2 cells with the Alexa Fluor 488-
labeled N20- anti-GRP78 primary antibody.(24) The FITC-Pep42 displayed comparable binding to 
the HepG2 cells as the anti-GRP78 antibody. Moreover, the binding of both the GRP78 primary 
antibody (100 nM) and the FITC-Pep42 to the HepG2 cells were found to be blocked comparably 
when the HepG2 cells were pretreated in the presence of the N-20 GRP78 blocking peptide. These 
results confirm the HepG2 cell surface binding specificities of Pep42 for the GRP78 receptor 
(Figure 3.7). Also of note, Pep42 was found to penetrate poorly in HepG2 cells, limiting its 
function to cell surface binding activity. Cell uptake efficiency may be enhanced by the 
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incorporation of the poly(arginine) sequences that are known to function as cell penetrating 
peptides.(24) Thus, Pep42 remains an efficient GRP78 cell surface binding ligand and its 
internalization capabilities may be further enhanced by the incorporation of polyarginine 
sequences.  
The toxicity of Pep42 on the hepatocellular cancer cell line HepG2 was analyzed by a 
Trypan blue cell staining assay.(31) The cell death assay exhibited low cell death (Figure 3.5) after 
treatment with Pep42 (0.15 mM). Taken together, all the findings highlight the potential use of 
Pep42 as a cancer targeting peptide for the detection and treatment of GRP78-harboring tumors. 
 
3.6. CONCLUSIONS 
In this chapter, the synthesis, characterization and biological evaluation of the GRP78 
targeting peptide Pep42 on the HepG2 cell line has been studied. The selection of Pep42 as a cancer 
targeting cyclic peptide was first revealed by Janda and co-workers as a highly selective ligand for 
the GRP78 surface receptor on melanoma cells through phage display bio-panning.(14)  With the 
use of a polar, poly(ethylene glycol)-based resin (NovaPEG), Pep42 and its FITC-labeled 
derivatives were successfully synthesized in good yields (14-24%) and purities (>95%) following 
RP-HPLC and ESI-MS analyses and separation. Flow cytometry revealed comparable binding 
abilities of FITC-Pep42 to GRP78 when compared to the Alexa Fluor 488-labeled N20-anti-
GRP78 primary antibody. The GRP78 binding interactions were abolished when the HepG2 cells 
were pretreated with a N20-GRP78 peptide blocker, indicating GRP78 binding specificity for the 
Pep42 sequence on the HepG2 cells. Moreover, a C-terminal activation procedure using NSC 
chemistry has been developed for the Pep42 sequence. This method not only resulted in the 
effective activation of peptides but may also be applied for the ligation of peptides onto bio-active 
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proteins, including B7H6. The latter is a focal point of our on-going studies (Chapter 4) aimed at 
the development of new GRP78-targeting ligands for cancer immunotherapy applications.  
 
3.7. MATERIALS AND METHODS 
3.7.1 MATERIALS 
Amino acids for the synthesis of all peptides, Fmoc-Arg(Pbf), Fmoc-Cys(Trt), Fmoc-Leu, 
Fmoc-Pro, Fmoc-Val, Fmoc-Gly, Fmoc-Tyr(t-Bu), Fmoc-Thr(t-Bu), Fmoc-Ala, and Fmoc-Ahx, 
were purchased from Novabiochem (San Diego, CA, USA), and Fmoc-NH-PEG3-Propionic Acid 
from aapptec (Lousville, KY). Peptide syntheses were conducted on a Rink Amide ChemMatrix 
(0.52 mmol/g) (Novabiochem, San Diego CA, USA). 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate, HCTU, was purchased from Advanced ChemTech 
(Louisville, KY, USA). Fluorescein isothiocyanate, FITC, was purchased from Advanced 
ChemTech (Louisville, KY) as a mixture of isomers and used in the dark to fluorescently label all 
peptides. Trifluoroacetic acid, TFA, (Biograde) was purchased from VWR (Radnor, PA, USA); 
N-N-dimethylformamide, DMF, was purchased from J.T. Baker (St. Lousville, KY). Acetonitrile, 
MeCN, and methyl alcohol, MeOH, dichloromethane, DCM, piperidine, N-methylmorpholine, 
triethylsilane (98+%), TES, were all purchased from Aldrich (Milwaukee, WI). Diethyl ether 
(99%, ACS), Et2O, used to precipitate peptides was purchased from Sigma Aldrich (St. Louis, 
MO, USA). All chemicals were used directly as received.  
 
3.7.2. PEPTIDE SYNTHESIS 
All peptides were synthesized by stepwise manual solid phase peptide synthesis using 
Fmoc-chemistry. Fmoc-amino acids (300 mol%, 0.16 mmol) were coupled on a Rink amide linker 
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poly(ethylene glycol) solid support (0.52 mmol/g, 0.05 mmols) for 20 minutes using [HCTU (300 
mol%, 0.16 mmol), NMM (600 mol%, 0.31 mmol) in DMF (4 mL). A 20% piperidine in DMF 
solution (4 mL) was used for Fmoc deprotection (10 min). Amino acid couplings and Fmoc 
deprotections were repeated until the desired sequences were completed. Peptide cleavage and 
deprotection from the solid support was accomplished using a mixture of TFA:TES:H2O, 
(95:2.5:2.5 v/v/v, 2 ml) for 4 h. Peptide samples were concentrated under nitrogen to a viscous oil, 
precipitated with cold Et2O, and centrifuged to a white pellet. The supernatant was decanted and 
the peptide pellets were dissolved in MeOH/H2O for LCMS analyses. For FITC labeling the resin 
containing peptide was swollen in DMF for 1 h. A slurry of FITC (1.1 equiv., 0.057 mmol) in 
pyridine/DMF/DCM (12:7:5 v/v) was prepared and added to the reaction vessel for overnight 
reaction on an overhead shaker. After FITC-labeling was completed, the resin was washed with 
DMF (3 x 3 mL), MeOH (3 x 3 mL), and DCM (3 x 3 mL). Sample analyses were performed on 
a Waters Alliance Separation Module 2695 and detected with a Waters 2998 photodiode array 
(PDA) detector at 214 nm, using a linear binary gradient (2-80% MeCN/H2O, 0.1% TFA, over 18 
min). Characterization was conducted on an Agilent 1100 series ESI-LCMS with single 
quadrupole mass analyzer and LC conditions which used a linear binary gradient (2-80% 
MeCN/H2O, 0.1% TFA, over 18 min) in positive mode. Analytical RP-HPLC was performed using 
a Zorbax RX-C18 (4.6 x 250 mm, 5 m particle size) or Waters 2695 Symmetry® C18 column 
(3.9 x 150 mm, 5m particle size), using the conditions previously described. Samples collected 
after purification were lyophilized to a white solid and re-dissolved in water to confirm purity and 
identity by LCMS analyses. 
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3.7.3. SYNTHESIS OF THE NSC DERIVED PEPTIDES 
DSC (65 mol, 16.6 mg) was dissolved in anhydrous DMF at room temperature, under N2 
conditions. The crude FITC derived peptides 22-24 (6.5 mol) were dissolved in dry DMF and 
trimethylamine (3.2 mol, 0.45 ml) was then added to the peptide solution. Peptide solutions were 
combined with the DSC/DMF mixture and reacted. The reaction mixture was stirred at room 
temperature for 1 h and quenched with 20 mL of TFA in water (1% volume/volume). Peptides 
were analyzed by RP-HPLC using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 5 m 
particle size) with a linear binary gradient, 20-80% MeCN/H2O, 0.1% FA, over 18 min at 25°C, 
with a 1 mL/min flow rate and detection at 220 nm. Peptide purities and identities were confirmed 
by LCMS as described above.    
 
3.7.4. CELL LINES AND CELL CULTURE 
The human hepatocellular carcinoma cells, cell line HepG2 (American Type Culture 
Collection, ATCC), were cultured in EMEM, (Sigma Aldrich) supplemented with 10% heat-
inactivated fetal bovine serum (Sigma Aldrich). Cell cultures were maintained at 75% confluency 
at 37°C in 5% CO2 humidified air. 
 
3.7.4. FLOW CYTOMETRY 
For detection of cell surface expression levels of GRP78 and binding of FITC-Pep42, the 
HepG2 cells were plated in 12-well plates with DMEM, at a 50,000 cell/well density, for 48 h at 
37 °C. HepG2 cells were further washed with PBS and dissociated with dissociation buffer (Life 
Technologies Corporation, Grand Island, NY). Cells were then re-suspended in FACS buffer 
(PBS, 1% FBS), and labeled with either anti-GRP78 (N-20) mAb-AlexaFluor 488 (100 nM) or 
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FITC-Pep42 (100 nM), and incubated at room temperature for 30 minutes in the dark. Cells were 
then washed and analyzed by flow cytometry on a MACSQuant® analyzer (MiltenyilBiotec). For 
peptide blocking studies, HepG2 cells were initially treated with GRP78 N-20 blocking peptide 
(10 mg/ml) for 30 min (R.T.) followed by incubation with either anti-GRP78 (N-20) mAb-
AlexaFluor 488 (100 nM) or FITC-Pep42 (100 nM) for an additional 30 min (R.T., dark). Cells 
were finally washed with FACS buffer and analyzed by flow cytometry. 
 
3.7.5. CELL VIABILITY 
A Trypan blue cell viability assay was used to evaluate the survival of HepG2 cells 
following treatment with Pep42. HepG2 cells were incubated in 24-well plates, for 24 h, in serum-
free basal media and then incubated for another 48 h in the presence of Pep42 (0.15 mM) at 37 °C. 
Following treatment cells were treated with enzyme-free dissociation buffer, to detach them from 
the plates, for 3 min at 37 °C. Cells were further centrifuged and re-suspended in PBS and stained 
with Trypan blue 0.4% stain solution (100 l). Cell viability was determined by Trypan blue 
exclusion using a countess cell counter. Data was collected in replicate measurements (n ≥ 3), 
analyzed in GraphPad Prism 5.9, and statistically analyzed for variance (p < 0.05). 
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CHAPTER 4: CONTRIBUTIONS TO KNOWLEDGE AND FUTURE WORK 
4.1. CONCLUSIONS AND CONTRIBUTIONS TO KNOWLEDGE 
ACCOMPLISHED IN THIS THESIS 
4.1.1. THE DISCOVERY OF B7H6-DERIVED IMMUNOSTIMULATORY 
PEPTIDES OF LYMPHOCYTIC NK92-MI CELLS 
The design, synthesis, and characterization of a novel class of NK cell-dependent 
immunostimulatory peptides (IPs) derived from the binding site interface of B7H6 and NKp30 
have been described in Chapter 2.(14) A structure–activity relationship study revealed that the 
synthetic peptides disclosed in this study exhibited secondary structures that varied on the solvent 
system. The peptides encompassing the FG loop of B7H6 displayed the putative turn conformation 
in a TFE:H2O mixture that was expected to contribute to NKp30 receptor binding and activation 
of NK cells’ immunostimulatory activities. Flow cytometry analyses confirmed binding of the 
FITC-labeled B7H6 derived peptides to the NK cells at 10 M concentrations. Moreover, 
competitive binding experiments revealed partial displacement upon treatment with the anti-
NKp30 mAb suggesting NKp30 binding specificities for the B7H6 derived peptides. In order to 
determine the immunostimulatory capabilities of the peptides with the NK cells, an ELISA 
demonstrated that the short pentapeptide, TVPLN, and the peptide derived form the secondary 
structure of B7H6, TSMGFGVTPLK, notably stimulated the secretion of TNF- but not IFN-
Moreover, these peptides posed no observable cytotoxicity (apoptosis) to the NK92-MI cells. In 
spite of these desirable properties, none of the synthetic peptides were found to outperform the 
native, B7H6 ligand. Therefore, these studies have effectively produced a new class of B7H6-
derived immunostimulatory ligands for their potential applications in tumor immunotherapy.  
 
91 
 
4.1.2. PEP42, A CANCER-TARGETING PEPTIDE THAT RECOGNIZES CELL 
SURFACE GRP78 ON CANCER CELLS 
The synthesis, characterization and biological evaluation of the GRP78 targeting peptide 
Pep42 on the HepG2 cell line has been studied in Chapter 3.(15) The selection of Pep42 as a cancer 
targeting cyclic peptide was first revealed by Janda and co-workers as a highly selective ligand for 
the GRP78 surface receptor on melanoma cancer cells through phage display bio-panning.(16-18)  
With the use of a polar, PEG-based resin (NovaPEG), Pep42 and its FITC-labeled derivatives were 
successfully synthesized in good yields (14-24%) and purities (>95%) following RP-HPLC and 
ESI-MS. Moreover, Fmoc-SPPS was also used for the generation of C-terminal containing Pep42-
PEG peptides. These peptides contained a reactive Lys residue which was coupled to DSC to yield 
the NSC-activated peptides. These peptides are considered to be useful substrates for bio-
conjugation studies, including in the ligation of peptides with bio-active proteins.(19) In this study, 
the generation of NSC-derived Pep42 sequences was developed for their ligation with native 
B7H6.  Flow cytometry analyses revealed FITC-Pep42 having comparable binding capabilities to 
GRP78 when compared to the specific Alexa Fluor 488-labeled N20-anti-GRP78 primary 
antibody. The GRP78 binding interactions were abolished when the HepG2 cells were pretreated 
with a N20-GRP78 peptide blocker, indicating GRP78 binding specificity for the Pep42 sequence 
on the HepG2 cells. Taken altogether, this study opens an opportunity for the development of 
GRP78-targeting ligands for cancer immunotherapy applications.  
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4.2. FUTURE WORK  
4.2.1. RATIONAL DESIGN FOR THE DEVELOPMENT OF CANCER-
TARGETING IMMUNOSTIMULATORY PEPTIDE-PROTEIN CONJUGATES 
The evolution of synthetic biology has led to the development of protein biologics such as 
the monoclonal antibodies (mAb), small antibody fragments (Fab or Fc regions) and the antibody-
drug conjugates (ADC) that are widely used in cancer immunotherapy applications.(1) Recently, 
B7H6 has been identified as a tumor associated ligand and activator for the NKp30 receptor, found 
on the surface of activated and resting NK cells.(2) NKp30 is responsible for NK cell 
immunosurveillance and the secretion of pro-inflammatory cytokines, such as IFN- and TNF-
Thus, tumors that present the cell surface B7H6 antigen are effectively recognized by 
activated NK cells which triggers immunstimulatory activities that leads to the destruction of the 
targeted tumor cells. However, low levels B7H6 or the absence of cell surface B7H6 has been 
found in the more malignant, resilient tumors that have evolved NK-dependent resistance.(22) In 
these cases, metalloproteases function to shed B7H6 from the cancer cell surface, promoting tumor 
escape from NK-dependent immunosurveillance and the rise of tumor spread and malignancy. 
GRP78 is a chaperone protein overexpressed and cell surface localized on a wide range of tumors, 
where it promotes tumor initiation, progression and metastatic spread.(22) Therefore, GRP78 has 
been validated as a clinically relevant biomarker for the development of cancer-targeting ligands. 
Towards this end, the short, 13-mer cyclic peptide, Pep42, has been selected through phage display 
bio-panning as a specific GRP78 ligand.(16) Therefore, we propose the rational design and 
development of a novel class of cancer-targeting immunostimulatory peptide-protein (CTIPP) 
conjugates, containing the GRP78 targeting sequence Pep42 and B7H6 for NK cell binding and 
activation (Figure 4.1).  Furthermore, an aminohexanoic acid linker will be introduced at the N-
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terminus of the Pep42 sequences for FITC-labeling by Fmoc-solid phase peptide synthesis. A 
series of PEG-derived Pep42 sequences will be introduced as spacers, while a C-terminal Lys 
residue will allow for the chemical ligation of the Pep42 derived sequences and B7H6 using the 
well-established NSC chemistry.(19) In this case, the activated NSC-peptides are anticipated to 
ligate with any of the 10 Lys residues on B7H6 to form stable, irreversible urea linkages.  
 
Figure 4.1. Schematic representation of the CTIPP, with varying lengths of PEG units. 
 
4.2.2 PEPTIDE-PROTEIN CONJUGATION 
Our proposed approach for the formation of the conjugated B7H6-Pep42 sequence is also 
based on literature precedence.(19) We anticipate ligation of Pep42 onto B7H6 (Figure 4.2) to be 
achieved in similar fashion, by reacting B7H6 in PBS at pH 7.4 with the FITC-labeled Pep42-
PEG-derived sequences that have been activated to the NSC at the C-terminus. The anticipated 
formation of the peptide-protein conjugate will be analyzed by a combination of RP-HPLC, 10% 
Bis-Tris PAGE, and ESI-MS in order to confirm the extent and location of conjugation for the 
Pep42 sequences onto the B7H6 protein.  
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Figure 4.2. Schematic representation of the B7H6-Pep42 conjugation reaction.  
 
4.2.3. BIOLOGY OF THE CTIPP BIOCONJUGATES 
4.2.3.1. BINDING CAPABILITIES OF THE CITPP CONJUGATES ON THE 
NK92-MI AND THE HEPG2 CELLS. 
The binding capabilities of the FITC-labeled CTIPP conjugates to the HepG2 and NK92-
MI cells will be initially determined by flow cytometry. Moreover, this study will also reveal the 
binding specificities of the CTIPP conjugates with the GRP78 and NKp30 receptors. The binding 
capabilities of the CTIPP conjugates will be compared to the soluble natural ligand, B7H6-Fc and 
the anti-NKp30 APC labeled mAb on the cell surface of the NK92-MI cells. The binding 
capabilities of the CTIPP conjugates will also be compared to that of the AlexaFluor 488-labeled 
N-20 anti-GRP78 mAb on the cell surface of the HepG2 cell line. These binding experiments will 
be initially performed independently and then in combination, in order to test the receptor binding 
specificities of the CTIPP conjugates when treated with and without the mAbs for GRP78 and 
NKp30. Taken together, these binding experiments will provide key insights into the binding 
occupancy and receptor binding specificities of the CTIPP conjugates for the GRP78 and NKp30 
receptors located on the surfaces of the HepG2 and the NK92-MI cells.  
 
4.2.3.2. IMMUNOSTIMULATORY ACTIVITIES OF THE NK92-MI CELLS. 
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The sustained capabilities of the CTIPP conjugates to elicit NK-dependent 
immunostimulatory activities will be assessed by measuring the secreted amounts of the 
inflammatory cytokines TNF-, IFN- and IL-6, and will be compared to that of the soluble natural 
ligand B7H6-Fc by a standard ELISA.(24)  
 
4.2.3.3. NK92-MI AND HEPG2 CELLS’ VIABILITY. 
A Guava-Nexin® Reagent (EMD Millipore), designed to assess early and late-stage 
apoptosis by flow cytometry, will be used to evaluate the cytotoxicity of the CTIPP conjugates on 
the HepG2 and NK92-MI cells.(25) Either the NK92-MI cells or the HepG2 cells will be incubated 
with the CTIPP conjugates in a concentration dependent manner and evaluated for the presence of 
apoptotic events by flow cytometry analyses.   
 
4.2.3.4. CTIPP DEPENDENT NK92-MI CELL MIGRATION AND 
CYTOTOXICITY 
Co-culture assays of the effector (NK92-MI) and target (HepG2) cells with and without the 
CTIPP conjugates will provide important information on the NK92-MI cell migration, 
immunistimulatory and cytotoxicities onto the HepG2 cells.(26) NK92-MI cell migration will be 
measured within transwell migration chambers, confocal fluorescence microscopy will provide 
images indicating the cell-in-cell structures, and the D275/propidium iodide dyes will provide 
information on cytotoxicity by counter-staining dead vs. live cells. 
  
4.2.3.5. IN-VIVO BIOLOGICAL ACTIVITY 
The in vivo studies of the CTIPP conjugates will be conducted in mice xenograft models 
transplanted with the HepG2 cells and the NK92-MI cells in order to analyze the influence of the 
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bioconjugates on tumor size and systematic immunological events. Mice toxicity, pharmacokinetic 
and tissue distribution properties will also be evaluated by adopting methods described in the 
literature.(27) 
 
4.2.4. DESIGN, SYNTHESIS, CHARACTERIZATON AND BIOLOGICAL 
EVALUATION OF AN NKP30 DERIVED CANCER TARGETING PEPTIDES. 
4.2.4.1. RATIONAL DESIGN 
In an effort to develop a new class of CTPs, we propose the rational design of a library of 
short peptide sequences derived from the binding interface of B7H6:NKp30. The CTPs will 
combine amino acid residues present in the primary sequences and secondary structures of the 
NKp30 receptor binding domains. The crystal structure analysis of the NKp30-B7H6 binding 
interface revealed a receptor-ligand stoichiometry of 1:1, encompassing twelve NKp30 amino acid 
residues bound to eleven B7H6 residues.(2) The NKp30 receptor, a type I transmembrane protein, 
binds to B7H6 through the front and back -sheets of its C-like domain.(2) The amino acids located 
in the pocket of NKp30, and responsible for direct contact with B7H6, comprise residues from 
strands C and F, particularly the aminoacids in loops BC (residues 50-54, IGSVT), and FG (111-
114, EVLG), along with helix 2 (residues 80-86, LASSRFL) respectively. In particular, residues 
Gly51 and Val 53 engage in the only two hydrogen bond interactions, and Glu111 forms the only 
salt bridge, while residues Ile50, Gly51, Ser52, Val53, Leu80, Ser82, Phe85, Leu86, Glu111, 
Leu113, Gly114 complement binding via Van der Waals contacts (Figure 4.2).(2) 
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Figure 4.3. The NKp30:B7H6 interface. Stereo view of the NKp30-B7H6 interface. The side 
chains interacting residues are shown in ball-and-stick representation, with carbon atoms in cyan 
(NKp30) or orange (B7H6), nitrogen atoms in blue and oxygen atoms in red. Hydrogen bonds are 
drawn as dotted black lines. A salt bridge linking residues NKp30 Glu111 and B7H6 Lys130 is 
shown as a solid black line. Figure adapted from J. Exp. Med. 2011, 208, 703-714.(2) 
 
Based on the described interaction in between the NKp30:B7H6,(2) the primary amino acid 
residues participating in binding, as well as the residues that were found to be adjacent to the 
binding hotspots and that promote secondary structure stability were selected as the lead amino 
acid residues for making a small library of peptides designed as B7H6-targeting peptides  (Table 
4.1). As such, B7H6-targeting peptides may encompass a new class of CTPs, useful for the 
selective detection and treatment of tumors that express the B7H6 antigen on the cell surface.  
 
 
Table 4.1. Sequence and structures of NKp30 derived peptides. 
98 
 
FITC-(CH2)5-FLH-CONH2 
 
FITC-(CH2)5-LASSRFLH-CONH2 
 
FITC-(CH2)5-IGSV-CONH2 
 
 
 
 
 
  
FITC-(CH2)5-IGSVTW-CONH2 
 
FITC-(CH2)5-RVEVL-CONH2 
 
FITC-(CH2)5-VCRVEVL-CONH2 
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4.2.4.2. SYNTHESIS AND CHARACTERIZATION OF THE NKP30 DERIVED 
SYNTHETIC PEPTIDES 
With the assistance of Francesca Romeo, BSc, and Andreich Darwich, undergraduate 
student at Seton Hall University, conventional Fmoc-SPPS was employed for the synthesis of 
NKp30-derived CTPs. Peptides were cleaved and deprotected from the solid support following 
synthesis, analyzed and purified by LCMS prior to biological studies. Peptides were recovered in 
isolated yields (1.5-13%) and purities (60-99%) according to RP HPLC. The identities of the 
synthetic peptides 28-35 were confirmed by mass spectrometry which validated sequence 
composition based on mass/charge ratios (Table 4.2). 
FITC-(CH2)5-ECRVEVLG-CONH2 
 
FITC-(CH2)5-RVEGRVEVLG-CONH2 
 
FITC-(CH2)5-IGSVEVLG-CONH2 
 
FITC-(CH2)5-LASSRFLAIGSVEVLG-CONH2 
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 Table 4.2. Characterization of the NKp30 derived synthetic peptides 28-35. 
Entry Sequence Crude 
purity (%)a, 
Isolated  
yield (%)b 
Purified 
purity (%)e 
MW (g/mol)c Zd RT (min)e RT 
(min)f 
28 FITC-NH-(CH2)5FLH-CONH2 
 
98 3.4 98 459.2  (916.7) 2 12.0 5.38 
29 FITC-NH-(CH2)5-IGSV-CONH2 
 
96 12 96 876.3 (875.6) 1 14.0 7.56 
30 FITC-NH-(CH2)5-RVEVL-CONH2 
 
97 13 97 558.8 (1115.7) 2 11.8 4.04 
31 FITC-NH-(CH2)5-IGSVTW-CONH2 
 
77 6.9 60 1163.3 (1162.9) 
388.8 (388.6) 
1 
3 
16.0 8.67 
32 FITC-NH-(CH2)5-ECRVEVLG-CONH2 66 2.0 98 703.3 (1405.2) 2 11.4 5.57 
33 FITC-NH-(CH2)5-LASSRFLH-CONH2 
 
52 1.5 96 716.3 (716.1) 
477.9 (477.4) 
2 
3 
10.3 5.59 
34 FITC-NH-(CH2)5-IGSVEVLG-CONH2 68 7.1 76 637.7 (1274.1) 2 16.5 8.41 
35 FITC-NH-(CH2)5-RVEGRVEVLG-CONH2 
 
80 7.2 99 539.0 (1614.5) 3 9.74 5.54 
aCrude purities by RP-HPLC at 220 nm using 20-80% MeOH/H2O with 0.1% FA over 18 min. 
bIsolated yields based on the resin loading. 
cObserved mass (expected mass) as [M + H]+/Z detected by LCMS in positive mode. 
dCharged state of the peptides as detected by LCMS in positive mode. 
eRetention times using 20-80% MeOH/H2O (0.1% FA) over 18 min. 
fRetention times using 20-80% MeCN/H2O (0.1% FA) over 18 min. 
 
4.2.4.3. BIOLOGICAL STUDIES 
Administration of the FITC-labeled NKp30 derived peptides to the HeLa cells, known to 
express cell surface B7H6 will be conducted to determine the extent of B7H6 binding on the HeLa 
cells. Their binding capabilities on the cell surface of the HeLa cells will be compared with and 
without commercially available anti-B7H6 PE labeled mAb in a concentration dependent manner. 
Their binding specificities will be tested with the fluorescently labeled NKp30, where inhibition 
on the binding of the peptides will confirm specificity to the cell surface antigen B7H6. The 
cytotoxicity of the CTPs on the HeLa cells will be evaluated by flow cytometry by measuring early 
and late apoptotic events with the Guava-Nexin® Reagent (EMD Millipore). 
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FIGURE A65. RP-HPLC analysis of crude peptide 22, 2-80% MeOH/H2O (0.1% FA) 
over 18 min.  
176 
FIGURE A66. ESI-LCMS analysis of crude peptide 22.  177 
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FIGURE A75. ESI-LCMS analysis of crude FITC labeled peptide 25.  186 
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FIGURE A76. RP-HPLC analysis of crude FITC labeled peptide 26, 2-80% MeCN/H2O 
(0.1% FA) over 18 min.  
187 
FIGURE A77. RP-HPLC analysis of crude FITC labeled peptide 26, 2-80% MeOH/H2O 
(0.1% FA) over 18 min.  
188 
FIGURE A78. ESI-LCMS analysis of crude FITC labeled peptide 26.  189 
FIGURE A79. RP-HPLC analysis of crude FITC labeled peptide 27, 2-80% MeCN/H2O 
(0.1% FA) over 18 min.  
190 
FIGURE A80. RP-HPLC analysis of crude FITC labeled peptide 27, 2-80% MeOH/H2O 
(0.1% FA) over 18 min.  
191 
FIGURE A81. ESI-LCMS analysis of crude FITC labeled peptide 27.  192 
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